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PREFACE 
The dissertation was submitted as part of the requirements for obtaining a PhD degree 
at the Doctoral PhD school at Aalborg University, Denmark. The work was conducted 
as an industrial PhD project in collaboration between Aalborg University, Aalborg, 
Denmark and the pharmaceutical company H. Lundbeck A/S, Valby, Denmark. The 
project was partly funded by the Innovation Fund Denmark under file no.: 5189‐
00044B and was carried out between October 2016 and December 2019. The principal 
supervisor was Associate professor Allan Stensballe, Department of Health Science 
and Technology, Aalborg University. The primary and secondary company 
supervisors were principal scientists Christiane Volbracht and Ayodeji Abdur-
Rasheed Asuni, Neuroscience, H. Lundbeck A/S.  During the PhD project, a three-
month scientific visit was arranged with Dr. Kelly Rogers, Division head; Head, 
Centre for Dynamic Imaging, Walter and Eliza Hall Institute of Medical Research, 
Australia.  
The main aim of the project was to elucidate the molecular features of senile plaques 
in Alzheimer’s disease and how these are modulated by a target specific antibody. 
The findings resulted in two publications and one manuscript of which the dissertation 
is based on:   
I. J. Bastrup, S. Birkelund, A.A. Asuni, C. Volbracht, A. Stensballe. Dual 
strategy for reduced signal suppression effects in MALDI mass 
spectrometry imaging. Rapid Communications in mass spectrometry. 
II. J. Bastrup, K. Kastaniegaard, A.A. Asuni, C. Volbracht, A. Stensballe. 
Proteomic and unbiased post-translational modification profiling of 
amyloid plaques and surrounding tissue in a transgenic mouse model of 
Alzheimer’s disease. Journal of Alzheimer’s disease. 
III. J. Bastrup, K.H. Hansen, T.B.G. Poulsen, K. Kastaniegaard, A.A. 
Asuni, S. Christensen, A. Stensballe, C. Volbracht. Anti-Aβ antibody 
treatment with Aducanumab modified the proteome of senile plaques 
and surrounding tissue and altered disease progression in a transgenic 
mouse model of Alzheimer’s disease. Manuscript in preparation. 
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ARIA: Amyloid-related imaging abnormalities  
1,5-DAN: 1,5-Diaminonaphthalene 
2,5-DHA: 2′,5′-dihydroxyacetophenone 
3- or 11pE: N-truncated and pyroglutamate modified Aβ 
4-HT: 4-Hydroxy-TEMPO  
Aβ: Beta-amyloid 
Ach: Acetylcholine 
AD: Alzheimer’s disease 
APH1: Anterior pharynx-defective 1 
APOE: Apolipoprotein E 
APP: Amyloid precursor protein 
APS: Ammonium persulfate  
BACE1: β-secretase  
BIN1: Bridging integrator-1 
BSA: Bovine albumin serum 
CDR-SB: Clinical Dementia Rating-Sum of Boxes  
CHCA: α-cyano-4-hydroxycinnamic acid 
CID: Collision-induced dissociation 
CLU: Clusterin 
CSF: Cerebrospinal fluid 
DDA: Data-dependent acquisition 
DIA: Data-independent acquisition 
DMSO: Dimethyl sulfoxide  
EDTA: Ethylenediaminetetraacetic acid 
ENO1: Enolase-1 
EOAD: Early-onset Alzheimer's disease 
ESI: Electrospray ionization  
FAD: Familial Alzheimer’s disease 
FDA: Food and Drug Administration  
FFPE: Formalin-fixed, paraffin-embedded 
GFAP: Glial fibrillary acidic protein 
GWAS: Genome-wide association study 
HCD: Higher-energy collisional dissociation 
I.p.: Intraperitoneal 
I.v.: Intravenous 
IgG(1): Immunoglobulin G (subclass 1)  
IMS3: Trimodal MALDI-MS imaging 
ISD: In-source decay 
ITO: Indium-tin oxide  
LC-MS/MS: Liquid chromatography tandem-mass spectrometry  
LCP1: Plastin-2 
LFQ: Label-free quantification 
LMD : Laser capture microdissection 
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LOAD: Late-onset Alzheimer's disease 
M/z: Mass-to-charge 
MALDI-MS: Matrix-assisted laser desorption/ionization mass spectrometry 
MCI: Mild cognitive impairment 
MRI: Magnetic resonance imaging  
NA: Numerical aperture 
NCT: Nicastrin 
NFT(s): Neurofibrillary tangle(s) 
NMDAr: N-methyl-D-aspartate receptor  
NME1: Nucleoside diphosphate kinase A  
NS: Normal swine serum 
O/N: Over night 
Ox: Oxidation 
PA: Phosphoric acid 
PASEF: Parallel accumulation serial fragmentation 
PBS: Phosphate-buffered saline 
PCA: Principal component analysis 
PEN2: Presenilin enhancer 2  
PET: Positron-emission tomography 
PFA: Paraformaldehyde 
PGK1: Phosphoglycerate kinase 1  
PiB: Pittsburgh compound B 
PIP5K1C: Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma 
ProExM: Protein-retention expansion microscopy  
PSEN1/2: Presenilin protein 1 and 2 
PTM: Post-translational modification 
Pyro-glu: Pyroglutamate 
RT: Room temperature 
S/N: Signal-to-noise 
SA: Sinapinic acid 
SAD: Sporadic Alzheimer’s disease 
SAβPP: Soluble beta-amyloid (Aβ) precursor protein 
SDC: Sodium deoxycholate 
SDCBP: Syntenin-1 
SDHB: Super-2,5-dihydroxybenzoic acid 
TEMED: Tetramethylethylenediamine 
TFA: Trifluoroacetic acid 
Tg: Transgenic 
TIC: Total Ion Count (or current) 
TIMS: Trapped ion Mobility Spectrometry 
TMT: Tandem mass tag  
TOF: Time-of-flight 
ToF-SIMS: TOF secondary ion mass spectrometry 




Alzheimer’s disease (AD) is a degenerative brain disease characterized by neuronal 
loss and progressive accumulation of neurofibrillary tangles and senile plaques. Senile 
plaques are composed of 38-43 residue beta-amyloid (Aβ) peptides and deposition of 
these occur in the initial stages of AD. This highlights an association between senile 
plaques and initiation of biological processes that affect the following pathological 
events in AD.  
We set out to 1) investigate the molecular composition of senile plaques at both a 
peptide, protein and modification level and 2) investigate whether the molecular 
composition was affected by a treatment with anti-Aβ targeting antibodies.  
We used two optimized tissue-based approaches, matrix-assisted laser desorption-
ionization mass spectrometry (MALDI-MS) imaging and a microproteomic approach 
that combined laser microdissection and liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Initial experiments were performed on frozen tissue 
biopsies from AD brains and from a transgenic (tg) mouse model of AD, the 
tgAPPPS1-21 mouse model. This mouse model expresses human proteins with 
mutations causing a hereditary form of AD referred to as familial AD (FAD). Our 
approaches were used to elucidate whether treatment with the antibody aducanumab 
could change the proteomic profile of senile plaques in tgAPPPS1-21 mice.  
We demonstrated that addition of phosphoric acid (PA) as matrix additive to the 
super-2,5-dihydroxybenzoic acid (DHB) matrix, significantly improved the signal-to-
noise ratio of Aβ1-42 peptides. Our data indicated differences in the peptide 
composition of Aβ species in senile plaques from AD and tgAPPPS1-21 brains by 
encompassing more truncated and modified Aβ proteoforms in AD.  
Our microproteomic approach identified a total of 555 proteins co-localizing with 
senile plaques from tgAPPPS1-21 mice. We identified 27 proteins that were 
significantly regulated by comparing the respective protein levels to adjacent control 
regions in the tissue. The regulated proteins were associated with cellular processes 
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such as metabolism and endocytosis. Furthermore, our analysis enabled identification 
of several exclusive post-translational modifications (PTM) like oxidation, 
deamidation and pyroglutamylation on proteins co-localizing with senile plaques from 
the tgAPPPS1-12 mouse brain tissue.  
Our chronic treatment with aducanumab reduced the senile plaque load in the 
hippocampus of tgAPPPS1-21 mice. Using microproteomics, we identified several 
proteins associated with molecular processes that were modulated by aducanumab. 
These proteins were associated with metabolism and phagocytosis and were 
especially regulated in the closely surrounding penumbra of senile plaques.  
Our results provide a novel understanding of the complex layers at peptide aggregate, 
proteome and PTM levels in senile plaques from tgAPPPS1-21 mice.  It is considered 












Alzheimers sygdom (AD) er en degenerativ hjernesygdom, der er kendetegnet ved 
celletab og en gradvis ophobning af neurofibrillære sammenfiltringer samt plak 
dannelse. Plak indeholder 38-43 lange beta-amyloid (Aβ) peptider og ophobning af 
plak forekommer i de indledende stadier af AD. Dette indikerer en sammenhæng 
mellem plak og initiering af biologiske ændringer, der igangsætter den efterfølgende 
patologi i AD.  
Formålet med dette projekt var 1) at undersøge den molekylære sammensætning af 
plaks, både på et peptid-, protein- og modifikationsniveau og 2) at undersøge om den 
molekylære sammensætning kunne påvirkes af behandling med antistoffer rettet mod 
plaks.  
Vi benyttede to optimerede vævsbaserede metoder, matrix-assisted laser desorption-
ionization mass spectrometry (MALDI-MS) imaging og en mikroprotein analyse, der 
kombinerede laser dissektion og liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). I de indledende forsøg anvendte vi frosne vævsbiopsier fra AD hjerner 
og fra en transgen musemodel for AD, tgAPPPS1-21. Denne musemodel udtrykker 
humane proteiner med mutationer der medfører en arvelig form af AD, også kaldet 
familiær AD (FAD). Vores metoder blev anvendt for, at undersøge om behandling 
med antistoffet aducanumab kunne ændre proteinprofilen af plaks i tgAPPPS1-21 
musene.  
Vi viste, at brugen af phosphorsyre som matrixadditiv til super-2,5-dihydroxybenzoic 
acid (DHB) kunne forbedre signal-til-støj-forholdet af Aβ1-42 peptidet signifikant. 
Vores data indikerede en forskel mellem plak fra AD og tgAPPPS1-21 mus på et 
peptidniveau, hvor mængden af afkortede og modificerede Aβ former var større i AD.  
Vores mikroprotein analyse identificerede 555 proteiner, som lokaliserede sig 
sammen med plak i tgAPPPS1-21 musene. Vi identificerede 27 proteiner, som var 
signifikant regulerede ved at sammenligne de respektive proteinniveauer til 
nærliggende kontrol områder i vævet. Disse proteiner var associeret til cellulære 
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processer som metabolisme og endocytose. Desuden fandt vores analyse eksklusive 
posttranslationelle modifikationer (PTM) så som oxidering, deamidering og 
pyroglutamat på proteiner, der lokaliserede sammen med plaks fra hjernevæv fra 
tgAPPPS1-21 musene.  
Vores længerevarende behandling med aducanumab reducerede mængden af plak i 
hippocampus området i tgAPPPS1-21 musene. Her muliggjorde vores mikroprotein 
analyse identificering af adskillige proteiner, der var påvirket af aducanumab 
behandlingen. Disse proteiner var blandt andet associeret til metabolisme og 
phagocytose og var specielt reguleret i den omkringlæggende plakpenumbra.  
Vores resultater giver en ny forståelse af den molekylære kompleksitet, der 
forekommer på peptid-, protein- og modifikationsniveau i plak hos tgAPPPS1-21 
mus. Det vurderes at denne information kan understøtte udviklingen af nye 
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CHAPTER 1. BACKGROUND  
1.1. ALZHEIMER’S DISEASE (AD): PREVALANCE, CLINICAL 
SYMPTOMS AND ETIOLOGY 
Dementia is characterized by progressive impairment of cognition, function and 
behavior. It has been estimated that more than 46 million people in the world are 
currently living with dementia and that the total cost to society was US $818 billion 
in 2015 (Prince, Wimo, Ali, Wu, & Prina, 2015). Alzheimer’s disease (AD) is the 
most common type of dementia, accounting for approximately 60-70% (World Health 
Organization, 2017) and is therefore responsible for a large number of dementia cases. 
Although AD was first described more than hundred years ago, to date, only 
symptomatic treatments exist which aim to counterbalance the neurotransmitter 
disturbance and thus no cure exists. 
The development of AD can be divided into four stages; preclinical, mild dementia, 
moderate dementia and severe dementia. At the preclinical stage, daily activities are 
not significantly affected but mild impairment of planning, ability to acquire new 
information, accessing general knowledge (semantic memory) and episodic 
depressive dysphoria may occur. At the mild dementia stage, a notable decrease in 
learning and memory occurs together with mild impairment of daily activities, 
language and spatial disorientation (Förstl & Kurz, 1999). At the moderate dementia 
stage, a significant impairment of daily activity occurs. Patients progressively lose 
insight into their current disease state and experience incapability of recognizing 
relatives. The severe dementia stage is characterized by severe memory loss and 
significant reduction of nearly all cognitive functions. Communication can be reduced 
to a limited use of words and patients may start to depend on assistance in basic daily 
activities such as help to chew and swallow while eating (Förstl & Kurz, 1999). It has 
been estimated that the average time from diagnosis to death is three to nine years, 
strongly associated with the age at diagnosis (Brookmeyer, Corrada, Curriero, & 
Kawas, 2002). A variety of environmental and genetic factors have been associated 
with AD. The disease is characterized as either familial early onset (EOAD; FAD) or 
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sporadic late-onset (LOAD; SAD). Autosomal-dominant mutations in the amyloid 
precursor protein (APP), Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) genes are 
associated with EOAD (Chartier-Harlin et al., 1991; Rogaev et al., 1995; Sherrington 
et al., 1996). The genetic factors involved in SAD are complicated in that genome-
wide association studies (GWAS) have identified several potential loci (at least 29 
loci) that increases the risk of developing SAD (Jansen et al., 2019; Lambert et al., 
2013). These single-nucleotide variants are observed in genes such as apolipoprotein 
E (APOE), clusterin (CLU), and bridging integrator 1 (BIN1).  
1.2. NEUROPATHOLOGICAL HALLMARKS OF AD 
1.2.1. MACRO- AND MICROSCOPIC CHARACTERISTICS 
Macroscopic examination of an AD brain reveals a characteristic pattern of brain 
dystrophy. This appears particularly as cortical atrophy and thinning, and dilation of 
the lateral ventricles (Figure 1-1A; (Serrano-Pozo, Frosch, Masliah, & Hyman, 
2011)). At a microscopic level, positive and negative lesions can be observed. The 
positive lesions include: 1) extracellular senile plaques (also referred to as amyloid 
plaques) that are mainly composed of 38-43 residue beta-amyloid peptides (Aβ; 
Figure 1-1B). 2) Neurofibrillary tangles (NFTs) and neuropil threads, which are both 
intracellular inclusions made of aggregated and hyperphosphorylated tau (Figure 
1-1C) and 3) dystrophic neurons. The negative lesions include loss of neurons, 
neuropil regions and synaptic elements (Serrano-Pozo et al., 2011).  
Longitudinal studies assessing cognitive evaluation together with biomarkers in 
cerebrospinal fluid (CSF) and advanced imaging techniques such as positron emission 
tomography (PET) imaging have identified a preclinical phase in AD occurring 10-
20 years before clinical symptoms initiates (Jack et al., 2010). The PET studies have 
for example used an amyloid PET ligand (Pittsburgh compound B (PiB)) to measure 
the amyloid deposition (Klunk et al., 2004). In this prodromal phase, changes in Aβ 
accumulation and subsequently NFTs have been identified, highlighting the 




Figure 1-1: A) Anatomical comparison of healthy brain and Alzheimer’s disease 
(AD) brain. Shrinkage of the cerebral cortex (1) accompanied by enlarged ventricles 
(2) is detectable at a macroscopic level in AD (right). Senile plaques (B) and 
neurofibrillary tangles (C) are detectable at a microscopic level. Scale bar = 40 µm. 
D) Hypothetical modeling of AD trajectory. By using different techniques, the 
presence and progression of different biomarkers, beta-amyloid (Aβ), CSF tau, 
atrophy by magnetic resonance imaging (MRI) and cognitive impairment, can be 
outlined. Positron emission tomography (PET) can be used to observe radioactive 
tracers like the Pittsburgh compound B (PiB; grey) that is a radioactive analog to the 
amyloid-binding compound thioflavin-T. These changes are thought to initiate the 
tau-associated pathology which causes release of the tau protein from dying neurons 
that can be detected in the cerebrospinal fluid (CSF; blue). The tau-associated 
pathology is followed by brain atrophy measured by MRI (yellow). Mild cognitive 
impairment (MCI) and symptoms of AD will occur over time. Genetic factors can 
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affect the presence of these biomarkers and thereby affect the progression of the 
disease. Figure 1A-C was modified from (DeTure & Dickson, 2019) with permission 
from the copyright owner (Springer Nature; under terms of the Creative Commons 
Attribution 4.0 International License1. Figure 1D was made by Joakim Bastrup and 
modified from (Fan, Brooks, Okello, & Edison, 2017; Jack et al., 2010). 
Amyloid-β peptides, aggregation and senile plaque deposition 
Several hypotheses have been formulated to explain mechanisms leading to AD 
pathogenesis. The widely accepted “amyloid cascade hypothesis” states that a chronic 
imbalance between the production and clearance of Aβ peptides leads to increased 
levels and deposition of Aβ peptides in the prodromal phase of AD (Hardy & Selkoe, 
2002; Masters, Simms, Weinman, Multhaupt, & Mcdonald, 1985). The Aβ peptide is 
derived from the integral membrane APP in a sequential cleavage process by two 
enzymes. First, beta (β)-secretase (BACE1) cleaves APP at the N-terminal of Aβ, 
resulting in a membrane-anchored C-terminal fragment of AβPP and release of a 
soluble APP fragment (Figure 1-2). Second, the anchored AβPP fragment is cleaved 
by gamma (γ)-secretase complex, consisting of PSEN1 or PSEN2, anterior pharynx-
defective 1 (APH1), nicastrin (NCT) and presenilin enhancer 2 (PEN2) (reviewed by 
(Annaert & De Strooper, 2002); Figure 1-2).    
The C-terminal cleavage by γ-secretase can vary and therefore result in generation of 
different variants of Aβ such as Aβ1-38, Aβ1-40, Aβ1-42, Aβ1-43. The anchored 
AβPP can also be cleaved by alpha (α)-secretases that results in sAPPα. This variant 
(sAPPα) has been reported to have neuroprotective functions and cleavage through 
this pathway is considered the non-amyloidogenic pathway (Furukawa et al., 2002). 
The Aβ peptide contains both hydrophilic and hydrophobic domains which is 
explained by the extracellular and transmembranal location of APP. However, these 
features also cause different aggregation properties of Aβ peptides, depending on the 
                                                          
1 http://creativecommons.org/licenses/by/4.0/ 
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length of the peptides (Barrow & Zagorski, 1991). The induced aggregation properties 
cause formation of oligomers, fibrils and eventually extracellular senile plaques. 
 
Figure 1-2: Graphical illustration of beta-amyloid (Aβ) sequence and processing from 
amyloid precursor protein (APP) to senile plaque (Aβ plaque). The transmembrane 
APP is cleaved by β-secretase and γ-secretase, leading to generation of an Aβ 
monomer. Aβ monomers can aggregate into oligomers (and protofibrils), Aβ fibrils 
and Aβ plaques. The different cleavage sites by secretases are illustrated by the 
arrows. The figure was modified from (Panza, Lozupone, Logroscino, & Imbimbo, 
2019) and made by Joakim Bastrup.   
Senile plaques are generally divided into two types, diffuse and neuritic plaques (also 
called dystrophic plaques). Diffuse plaques are deposited in a non-fibrillar 
conformation whereas the neuritic plaques are deposited in a fibrillar confirmation 
(Probst, Brunnschweiler, Lautenschlager, & Ulrich, 1987). Neuritic plaques are 
associated with surrounding degenerated neurites. Several studies have reported glial 
cell engagement of senile plaques, indicating that plaques are in close contact with the 
surrounding environment (Akiyama et al., 1999; Heneka et al., 2015). Furthermore, 
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proteins such as APOE, CLU and BIN1, have been reported to co-localize with 
aggregated Aβ, either directly or in close contact (De Rossi et al., 2019; Koistinaho et 
al., 2004; Oda et al., 1995). For example, APOE has been hypothesized to affect Aβ 
aggregation and clearance, whereas CLU has been reported to generate oxidative 
stress upon co-aggregating with Aβ (Koistinaho et al., 2004; Oda et al., 1995). BIN1 
on the other hand, has been reported to localize at a pathogenic region within 
periphery regions of senile plaques and thus not in direct aggregation with the entire 
unit of the plaque (De Rossi et al., 2019). These examples suggest a pathological 
relevance for some of the co-localizing proteins, as they can impact aggregation, 
clearance and spreading of Aβ (reviewed by (Atwood, Martins, Smith, & Perry, 
2002)) (Figure 1-3). 
Several reports have shown that Aβ aggregates mainly exist as truncated isoforms 
rather than full length Aβ peptides (Güntert, Döbeli, & Bohrmann, 2006; Liu et al., 
2006; Piccini et al., 2005). Among these, pyroglutamate (pyro-glu) modified Aβ 
isoforms are a predominant component observed in senile plaques in AD patients 
(Jawhar, Wirths, & Bayer, 2011; Moro et al., 2018). It has been suggested that pyro-
glu modified Aβ peptides accumulate in the brain at the earliest stages, before the 
appearance of clinical symptoms of AD, indicating that these peptides could potential 
be seeding species and thus play an important role in the subsequent aggregate 
formation (Sergeant et al., 2003). Pyro-glu modified Aβ is generated in a two-step 
process by first an N-terminal truncation at a glutamate residue followed by 
processing of glutaminyl cyclase that catalyze the generation of cyclic pyroglutamate 
(Jawhar et al., 2011). Despite the relevance of the pyro-glu modifications, Aβ peptides 
have also been reported to contain other post-translational modifications (PTMs) like 
racemization, isomerization, phosphorylation, nitration, dityrosine, glycosylation and 
oxidation (reviewed by (Kummer & Heneka, 2014)). One explanation for this variety 
of PTMs could be the extracellular location of aggregated Aβ peptides in which they 
are exposed to an extracellular environment and/or secreted enzymes (reviewed by 
(Atwood et al., 2002)). Additionally, given that several proteins infiltrate and interact 
with senile plaques, it is unknown whether such exposure is affecting the co-localizing 
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proteins. PTMs have been reported to change the confirmation and biological function 
of proteins (Jensen, 2004) and exposure to PTMs could therefore have significant 
impact on the biological processes occurring within and around senile plaques (e.g. 
affect the aggregation, clearance rate and/or seeding in a both beneficial or detrimental 
way (Figure 1-3)).   
 
Figure 1-3: Hypothetical illustration of proteins co-aggregating with beta-amyloid 
(Aβ). Proteins such as apolipoprotein E (APOE) and clusterin (CLU) have been 
reported to co-aggregate directly with Aβ and affect clearance, toxicity and 
deposition. Several post-translational modifications (PTMs) and truncation variants 
have been identified on Aβ, but it is unknown whether co-aggregating proteins are 1) 
also subjected to such  modifications and/or 2) are affected by PTMs or truncation of 
Aβ. Figure was made by Joakim Bastrup.  
Tau, NFT formation and relation to amyloid-β 
NFTs represent the second major hallmark of AD and arises from intraneuronal 
aggregates of the microtubule-associated protein tau. Tau is encoded by the MAPT 
gene and functions as a stabilizing phosphoprotein that contributes to the assembly 
and structure of axonal microtubules and neuronal transport (reviewed by (Zempel & 
Mandelkow, 2014)). The human tau protein can be spliced into six isoforms that are 
differentially expressed throughout the development of the brain (Goedert, Spillantini, 
Potier, Ulrich, & Crowther, 1989). Under pathological conditions tau can undergo 
MOLECULAR COMPLEXITY OF SENILE PLAQUES IN ALZHEIMER’S DISEASE:   CAN IT BE MODULATED BY A 
TARGETED ANTIBODY? 
22 
multiple PTMs such as hyperphosphorylation, further mis-localization, 
oligomerization, and aggregation events. Tau aggregation can lead to several forms 
such as paired helical filaments, twisted ribbons and straight filaments that 
consequently form NFTs in AD (Goedert, Spillantini, Cairns, & Crowther, 1992; 
Goedert, Spillantini, & Crowther, 1991). The formation and spreading of NFTs in the 
brain of AD patients is believed to disrupt normal tau function and result in synapse 
loss, neuronal death and cognitive impairment. The appearance of NFTs in different 
brain regions is classified into stages of AD (Braak & Braak, 1991). Importantly, the 
level of NFTs in the neocortex correlates with the cognitive decline in AD which is 
different from the Aβ-associated pathology (Nelson, Braak, & Markesbery, 2009). 
Recent reports suggest that the tau-associated pathology propagates throughout the 
AD brain via neuronal circuits in a prion like manner (reviewed by (Zempel & 
Mandelkow, 2014)).  
The relationship between Aβ accumulation and subsequent initiation of tau 
pathologies has long been debated. It has been found that Aβ dimers extracted from 
AD brains increase hyperphosphorylation of tau as well as neurodegeneration in a 
neuronal cell culture (Jin et al., 2011). Similarly, a recent study developed a three-
dimensional human stem-cell-derived culture system expressing FAD mutations, and 
observed hyperphosphorylated tau and tau aggregates after Aβ deposition (Choi et al., 
2014). Although these studies are not comprehensive, they indicate a link between Aβ 
and the tau-associated pathology.  
1.3. MOUSE MODELS MIMICKING THE AMYLOID-ASSOCIATED 
PATHOLOGY 
Transgenic (tg) mouse models have been generated to mimic core features of AD 
pathology such as Aβ accumulation and deposition. The design of several tg amyloid-
models is based on FAD mutations like the autosomal dominant mutations in the APP, 
PSEN1, or PSEN2 genes. These FAD mutations account for approximately 1% of all 
AD cases, with an established probability of 50% for developing AD when inherited 
one of the three mutations (reviewed by (Bateman et al., 2010)). The human and 
mouse APP share 97% sequence homology. Notably, the mouse Aβ sequence contains 
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three different amino acids compared to the human homolog (R5G, Y10F, H12R) that 
hinders Aβ overproduction and aggregation in mice (Xu et al., 2015). Thus, cloning 
the human FAD mutated APP gene into mice has been found necessary to model the 
excessive generation of Aβ seen in FAD patients. Overexpression of human APP 
without FAD mutations did not result in deposition of senile plaques mice (Mucke et 
al., 2000). Several models carrying different designs have been developed. The most 
common examples are the tg2576, tgAPPArcSwe and tgAPP23 models overexpressing 
human APP isoforms (APP695 or APP751) containing the double Swedish mutation 
(KM670/671NL) or the Swedish mutation in combination with the Artic mutation 
(E693G) (Hsiao et al., 1996; Lord et al., 2006; Sturchler-Pierrat et al., 1997). 
Similarly, the tgAPPPS1-21 and  tgPS2APP models have been generated to 
overexpress human APP with the Swedish mutation while also carrying either mutated 
human PSEN1 (L166P) or PSEN2 (N141I) (Radde et al., 2006; Richards et al., 2003). 
In general, these tg mice develop a robust senile plaque deposition throughout the 
brain and feature signs of gliosis that is observed in AD. However, these models show 
limited hyperphosphorylated tau and have not been reported to develop NFTs 
(reviewed by (Drummond & Wisniewski, 2017)). Additionally, global neuron loss 
(e.g. brain atropy) is also limited in these FAD models (Takeuchi et al., 2000). 
Therefore, these models do not recapitulate FAD, but rather mimic overproduction of 
Aβ and how the mouse brain environment copes with such accumulation. These 
models are widely used to support the development of new drugs targeting Aβ and it 
is considered important to investigate the translatability between these models, FAD 
and AD.        
1.4. TREATMENT STRATEGIES TARGETING AMYLOID-Β 
Currently, only symptomatic treatments for AD are available. These drugs are 
cholinesterase inhibitors and a N-methyl-D-aspartate receptor (NMDAr) antagonist 
that increase levels of acetylcholine (ACh) or block stimulation of the NMDAr, 
respectively (reviewed by (Godyń, Jończyk, Panek, & Malawska, 2016)). As these 
symptomatic treatments do not halt or delay the disease progression, there is an unmet 
need for finding new treatments. Therefore, disease-modifying drugs that can interfere 
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with the pathological steps leading to clinical symptoms, are currently of high interest 
and under extensive research. The amyloid cascade hypothesis postulates that several 
steps are involved in Aβ release, processing and formation of senile plaques (Figure 
1-2). These different stages contain promising targets because of the strong 
involvement of Aβ in the prodromal phase of AD. For example, the processing of APP 
involves secretases (BACE1 and γ-secretase) that can be inhibited. The aggregation 
process of monomers into oligomers, protofibrils and Aβ fibrils can also be inhibited, 
stopped or directed into increased degeneration by aggregation inhibitors. Further, the 
aggregation process from Aβ fibrils into senile plaques can be inhibited and targeted 
for increased clearance by anti-Aβ antibodies (reviewed by (Panza et al., 2019); 
Figure 1-4).    
Anti-Aβ immunotherapies aiming at increasing the clearance of Aβ species and senile 
plaques are currently one of the promising treatment concepts that enter phase III 
clinical trials. These include active or passive immunization strategies. Active 
immunization uses exposure to an Aβ antigen that triggers an immunological response 
that provokes the generation of antibodies against an Aβ epitope. One example of an 
active vaccine was AN-1792 that greatly reduced senile plaque burden, but introduced 
aseptic meningoencephalitis in few patients in a phase II trial (Nicoll et al., 2003; 
Schenk et al., 1999). The benefits of active vaccinations are the extended antibody 
response of polyclonal antibodies that limit the number of vaccinations while targeting 
multiple sites. On the other hand, a risk of producing adverse effects is present which 
was observed in the AN-1792 trial (Nicoll et al., 2003).  
The passive immunization strategies include administration of monoclonal or 
polyclonal antibodies that target different steps in the APP processing and senile 
plaque formation (Figure 1-4). Several antibodies such as bapineuzumab, 
solanezumab, gantenerumab, crenezumab and aducanumab have entered clinical trials 
but failed to reach the primary endpoints (reviewed by (Selkoe, 2019; van Dyck, 
2018)). Different hypotheses have been proposed for how clearance mechanisms are 
facilitated by the anti-Aβ immunotherapies. For example, the peripheral sink 
hypothesis postulates that antibodies facilitate the transport of Aβ peptides across the 
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blood-brain barrier into periphery by thriving towards creating an equilibrium 
between the brain and periphery (Zhang & Lee, 2011). In contrast, a central clearance 
mechanism has also been proposed where the degradation is mediated by glial cell 
engagement and/or antibody binding and inhibition of further aggregation or 
spreading of toxic oligomers (Bohrmann & Baumann, 2012; Sevigny et al., 2016).    
Two antibodies, gantenerumab and aducanumab, were of interest in this PhD thesis 
because they have shown promising results in preclinical animal models while having 
different target profiles and are investigated in clinical trials. A short introduction to 
both antibodies will be given in the following section. 
 
Figure 1-4: Graphical illustration of beta-amyloid (Aβ) processing as illustrated 
previously in (Figure 1-2). Each step can be targeted by different antibodies like 
gantenerumab and aducanumab. Figure was modified from (Panza et al., 2019) and 
made by Joakim Bastrup.   
1.4.1. TWO ANTIBODIES OF INTEREST, GANTENERUMAB AND 
ADUCANUMAB  
Gantenerumab or RG1450, is a human immunoglobulin G subclass 1 (IgG1) 
monoclonal antibody by Hoffman-La Roche with high binding affinity against a 
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conformational epitope on Aβ that includes both the N-terminal and mid region of Aβ 
peptides (sequence: AA 3-12 and AA18-27) (Bohrmann & Baumann, 2012). The 
antibody is hypothesized to recruit microglia and increase phagocytosis of aggregated 
Aβ. The initial phase I clinical trials showed removal of senile plaques measured by 
Aβ PET imaging (Ostrowitzki et al., 2012), although amyloid-related imaging 
abnormalities (ARIA) were of concern (e.g. vasogenic edema). Two phase III clinical 
trials, called GRADUATE 1 and 2 in early (prodromal to mild) AD patients, are 
currently ongoing.   
Aducanumab or BIIB037, is a human IgG1 monoclonal antibody by Biogen with high 
binding affinity against oligomeric and insoluble fibrillar Aβ1-42 (sequence: AA3-6) 
(Sevigny et al., 2016). Results from the initial phase I trial with a small cohort (n = 
165 patients) was very promising and showed significant clearance of senile plaques, 
visualized by Aβ PET imaging, and decelerating of cognitive decline measured by 
Clinical Dementia Rating-Sum of Boxes (CDR-SB) (Sevigny et al., 2016). Based on 
these positive findings, two phase III trials (Emerge and Engage) with larger cohorts 
of mild AD patients (n = 3200 combined) were conducted and showed efficient 
removal of senile plaques by PET imaging (reviewed by (Selkoe, 2019)). However, 
in the first analysis cognition measured by CDR-SB was not improved in patients 
receiving aducanumab, and thus the trials were terminated in spring 2019. The 
negative outcome of these aducanumab trials led to several questions around why 
cognitive decline was not slowed when Aβ deposition was efficiently removed as well 
as to the relevance of the amyloid cascade hypothesis in AD. Other points such as trial 
design, inclusion of patients with advanced Aβ pathology, or reliability of PET 
imaging have also been questioned (reviewed by (Selkoe, 2019)). However, in 
October 2019, based on a new analysis of a larger dataset from the discontinued 
studies, it was reported that aducanumab reduced patients’ clinical decline measured 
by CDR-SB significantly in the high-dose aducanumab group of the Emerge trial. 
Approval of aducanumab by the Food and Drug Administration (FDA) based on a 
single positive trial is pending. 
27 
These recent developments highlighted all the complexity of targeting Aβ in AD. It is 
also a reminder that we need a much better understanding of the underlying biology, 
as well as molecular markers that link to the disease and the prodromal phase of AD. 
Furthermore, we need tools that can elucidate the molecular effects of treatments that 
are in development. 
1.5. TISSUE-BASED APPROACHES TO INVESTIGATE THE 
COMPOSITION OF SENILE PLAQUES 
The amyloid cascade hypothesis postulates that excessive production and 
accumulation of Aβ over time leads to formation of senile plaques and subsequently 
triggers pathological and detrimental changes in brain function. Therefore, 
characterizing senile plaques within the tissue-associated environment is key to 
understanding the cellular and immunological interaction and subsequent pathological 
cascade of events in AD. Several technologies are available to elucidate this, but we 
reasoned that unbiased and hypothesis-free techniques such as RNA-sequencing or 
mass spectrometry are advantageous approaches because of their broad identification 
capabilities. Two mass spectrometry-based strategies have been used in the course of 
this PhD project and a general introduction and their previous applicability in relation 
to AD will be described in the subsequent sections. 
1.5.1. MALDI-MS IMAGING ANALYSIS OF SENILE PLAQUES 
Introduction to MALDI-MS 
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) was 
introduced in the mid 1980’s by discovering the capability of ionizing molecules by 
laser ablation in combination with UV light absorbing matrix compounds (Karas, 
Bachmann, & Hillenkamp, 1985; Karas & Hillenkamp, 1988; Tanaka et al., 1988). 
The fundamental principles of MALDI-MS are also applicable to MALDI imaging 
and a short introduction to MALDI-MS will therefore be described in this section.   
In MALDI-MS, a sample such as a peptide or protein mixture is mixed with a solution 
containing a sample matrix, usually an organic molecule having specific 
characteristics that enables its usability. The most important feature of the matrix is 
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to adsorb energy and facilitate ionization of the sample compound during irradiation 
by a laser beam without causing radiational damage to the specimen. Such high energy 
density within the matrix lattice results in a phase transition of the molecules from 
solid state into gas phase ions. Notably, this is a soft ionization with little increase in 
internal energy, meaning that little to no fragmentation occurs when analyzing 
molecules and thus ionized molecules are generally intact (Tanaka et al., 1988). After 
ionization, molecular ions can be detected by a mass analyzer and detector that 
determines the mass-to-charge (m/z) ratio of the ions. This is commonly based on a 
time-of-flight (TOF) measurement where the analytes are accelerated by an electric 
field and guided into a TOF mass analyzer (Tanaka et al., 1988). The electric field is 
uniform and applies the same amount of energy to all ions, meaning that the travel 
through the TOF mass analyzer is dependent on the m/z ratio of the ions. The 
information from this measurement can be presented as a mass spectrum depicting the 
intensity (number of ions) as a function of the m/z value.  
Commonly employed matrices for peptide and protein analysis are sinapinic acid (SA;  
(Ronald C. Beavis, Chait, & Standing, 1989)), α-cyano-4-hydroxycinnamic acid 
(CHCA; (R. C. Beavis, Chaudhary, & Chait, 1992)) and 2,5-dihydroxybenzoic acid 
(2,5-DHB; (Strupat, Karas, & Hillenkamp, 1991). The choice of matrix depends on 
the target molecule of interest as the matrix’ ability to adsorb/desorb and ionize 
different classes of molecules vary. The matrix compounds are commonly in a 
combination with an organic solvent (e.g. acetonitrile or methanol) and an organic 
acid (e.g. trifluoroacetic acid (TFA) or formic acid) that affect crystal morphology, 
reproducibility and signal-to-noise (S/N) ratio (Laugesen & Roepstorff, 2003). 
Different organic acids have been investigated to improve the matrix capabilities by 
enhancing sensitivity and reducing signal suppression effects. For example, 
phosphoric acid (PA) has been observed to enhance the detection of phosphopeptides 
and non-phosphopeptides in combination with the 2,5-DHB matrix (Kjellstrtöm & 
Jensen, 2004; Kuyama, Sonomura, & Nishimura, 2008; Park, Kim, Lee, Seo, & Kim, 
2013; Stensballe & Jensen, 2004).   
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Introduction to MALDI-MS imaging 
In 1997, Caprioli and colleagues showed that the spatial distribution of molecules 
could be mapped on sections from rat pituitary tissue by using MALDI-MS directly 
on the tissue, thereby introducing MALDI-MS imaging (Caprioli, Farmer, & Gile, 
1997). By taking advantage of MALDI-MS principles, MALDI imaging enables 
detection, identification and spatial distribution of a variety of different molecules. 
MALDI-MS imaging data is acquired by ablating the surface of a sample by a series 
of spots covering an area of interest by a predefined number of laser shots per x,y 
coordinate (reviewed by (Norris & Caprioli, 2013)). Each spot contains mass spectral 
data that together is used to generate a plot of ion intensities (single ion images) and 
enable visualization of molecules within the analyzed sample specimen at relative 
high resolution (Figure 1-5). Sample preparation steps such as handling, pretreatment, 
matrix type and deposition are important features in MALDI-MS imaging that affects 
morphological detail, analyte sensitivity and spatial resolution. For example, fresh 
frozen tissue cut at 3-20 µm thickness and mounted on conductive glass slides 
(indium-tin oxide (ITO)) are typically preferred to ensure an electrical conductance 
between tissue section and glass slide. Proper rinsing or washing of the tissue 
specimen is critical for removing signal suppressing molecules like salts and lipids 
that may affect crystallization or cause adduct formation (reviewed by (Norris & 
Caprioli, 2013)). Several washing steps are typically used when analyzing peptides or 
proteins in tissue to effectively reduce the interference of salts and lipids. One of these 
include a combination of ethanol and Carnoy’s fluid (chloroform, acetic acid and 
ethanol) (Yang & Caprioli, 2011). The choice of matrix compound, organic solvent, 
additive and matrix deposition method can affect the outcome of the analysis. Each 
type of matrix has advantages and disadvantages and thus identifying the optimal 
matrix is often depending on the tissue type and molecule species of interest (e.g. lipid 
or peptide (Kaya, Zetterberg, Blennow, & Hanrieder, 2018)). Several commercially 
available matrix deposition instruments exist such as the ImagePrep (Bruker 
Daltonics) and the TM-sprayer (HTX Technologies). One advantage with these 
robotic sprayers compared to manual deposition or sublimation is the possibility of 
adjusting the deposition settings (e.g. dry time; matrix wetness, microcrystal structure, 
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and layer thickness) and thereby designing the optimal matrix deposition for a given 
tissue sample and the applied matrix. Any changes in the deposition parameters will 
potentially introduce matrix variability between experiments. 
 
Figure 1-5: Matrix assisted laser desorption/ionization mass spectrometry (MALDI-
MS) imaging workflow. A sample specimen (here mouse brain) is sectioned and 
mounted to a conductive glass slide. An organic matrix solution is applied, and a series 
of spots are ablated with a laser beam. A mass spectrometer is used to detect the 
generated ions and create a mass spectrum for each spot. By combining mass spectral 
data from all spots single ion-images can be generated and used to visualize the spatial 
distribution of molecules of interest. Figure was made by Joakim Bastrup.  
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MALDI-MS imaging of senile plaques 
MALDI-MS imaging is reasoned to be advantageous for elucidating the senile plaque 
location and composition in tissues because it does not require multiple 
immunostainings. The use of MALDI-MS imaging to study Aβ peptides and 
aggregates have emerged over the last years (Table 1-1). Initially, Stoeckli and 
colleagues reported a method for spatial detection of Aβ peptides in brain tissue 
sections from tgAPP23 mice in 2002 (Stoeckli, Staab, Staufenbiel, Wiederhold, & 
Signor, 2002). The tissue sections were mounted on stainless-steel sample plates and 
the SA matrix was manually applied. This approach led to the detection of Aβ1-37, 
Aβ1-38, Aβ1-39, Aβ1-40, Aβ1-42 and Aβ1-42 Oxidized form (Ox) using the Voyager 
STR mass spectrometer (Applied Biosystems) (Stoeckli et al., 2002). Using a thin-
layer chromatography sprayer, Stoeckli and colleagues also showed the first 
fragmentation spectrum of Aβ1-42 on tissue using the CHCA matrix (Stoeckli et al., 
2006). In 2008, Seeley and colleagues reported similar ability to detect senile plaques 
by MALDI-MS imaging using several matrices (Seeley & Caprioli, 2008). In 2016, 
Kelley and colleagues reported a method for detecting Aβ peptides by laser-induced 
in-source decay (ISD) combined with MALDI-MS imaging with the purpose of 
avoiding subsequent conformational MS/MS analysis that was reported to be difficult 
in formalin-fixed, paraffin-embedded (FFPE) tissue (Kelley, Perry, Castellani, & 
Bach, 2016). Kelley and colleagues compared mass spectra from synthetic Aβ and 
isolated senile plaque material from FFPE AD brain and identified Aβ peptide 
fragments ((Kelley, Perry, Bethea, Castellani, & Bach, 2016; Kelley, Perry, 
Castellani, et al., 2016)). This approach enabled detection of several Aβ species (Aβ1-
16, Aβ1-24, Aβ5-40, Aβ14-40, Aβ1-42). Notably, a trypsin digest step was found 
necessary to detect Aβ species (Kelley, Perry, Castellani, et al., 2016). In contrast to 
the previous approaches, the brain tissue was mounted onto ITO conductive glass 
slides and on-tissue trypsin digest was performed prior to sublimation with the 2,5-
DHB matrix. Moreover, the analysis was acquired on a Ultraflextreme instrument 
(Bruker Daltonics) (Kelley, Perry, Bethea, et al., 2016; Kelley, Perry, Castellani, et 
al., 2016).  
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In 2016, Carlred and colleagues used MALDI-MS imaging on brain sections from a 
model carrying the Artic and Swedish mutation in AβPP (tgAPPArcSwe). Additionally, 
they used laser capture microdissection (LMD) and MALDI-MS to validate the mass 
of different Aβ peptides detected in the MALDI-MS imaging analysis (Carlred et al., 
2016). Their setup included fresh frozen tissue and the CHCA matrix that was applied 
with the ImagePrep sprayer. The analysis was performed on a Ultraflextreme 
instrument model (Carlred et al., 2016). The study detected several Aβ species without 
tryptic digest, including: Aβ1-42arc Ox, Aβ1-42arc, Aβ1-42arc Ox [M+2H]2+, Aβ1-
40arc [M+Na]+, Aβ1-40arc, Aβ4-43arc Ox, pyro-glu modified Aβ3-42, Aβ1-39arc, 
Aβ2-40arc, Aβ5-43 Ox, Aβ3-40arc [M+Na]+, Aβ3-40arc Ox, Aβ1-38arc [M+Na]+, 
Aβ1-38arc Ox, Aβ1-38arc, Aβ2-39arc, Aβ1-37arc, Aβ3-39arc Ox, Aβ1-36arc, Aβ11-
40arc, Aβ7-28arc, Aβ11-33arc.  
In 2016, Mendis and colleagues reported detection of lipid changes in AD brain 
compared to healthy control (Mendis, Grey, Faull, & Curtis, 2016). The study used 
sublimation with the 1,5-Diaminonaphthalene (1,5-DAN) matrix and analyzed the 
tissue specimens with the Ultraflextreme instrument. Both negative- and positive-ion 
modes were used on adjacent tissue sections to investigate lipids changes in the 
hippocampus (Mendis et al., 2016). In 2017, Kaya and colleagues similarly studied 
lipid changes in the tgAPPArcSwe mouse model of AD (Kaya, Brinet, Michno, Syvänen, 
et al., 2017). The study focused on detecting gangliosides and ceramides species using 
a similar experimental setup as reported by Mendies and colleagues (2016) (e.g. 1,5-
DAN matrix, sublimation, Ultraflextreme analysis in negative-ion mode (Kaya, 
Brinet, Michno, Syvänen, et al., 2017)). Kaya and colleagues did not detect senile 
plaques with MALDI-MS imaging but correlated the MALDI-MS imaging data with 
histological staining of senile plaques (Kaya, Brinet, Michno, Syvänen, et al., 2017; 
Kaya, Michno, et al., 2017). The same year, the group published a three-step method 
termed trimodal MALDI-MS imaging (IMS3) to study lipids and peptides within the 
same tissue section (Kaya, Brinet, Michno, Zetterberg, & Blenow, 2017). With IMS3, 
a dual polarity (both negative and positive-ion mode) was used on the same spot with 
1,5-DAN matrix followed by an additional analysis using a second matrix, 2′,5′-
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dihydroxyacetophenone (2,5-DHA), for peptide imaging on the Ultraflextreme 
instrument (Kaya, Brinet, Michno, Zetterberg, et al., 2017). By including the second 
matrix, the authors were able to detect Aβ1-37, Aβ1-38 and Aβ1-40 and correlate 
changes of lipids (sphingolipids, phospholipids and lysophospholipids) with senile 
plaques in the tgAPPArcSwe mouse model of AD (Kaya et al., 2018). The IMS3 
approach has further been optimized by including LMD and immunoprecipitation in 
combination with MALDI-MS to elucidate lipid changes in AD (Michno et al., 2018). 
Moreover, recent combinations with multimodal TOF secondary ion mass 
spectrometry (ToF-SIMS) and multivariate image analysis have indicated lipid 
associated differences across senile plaques in brain tissue from tgArcSwe mice 
(Michno, Wehrli, Zetterberg, Blennow, & Hanrieder, 2019).  
In 2017, Kakuda and colleagues analyzed AD patient tissue with MALDI-MS 
imaging to visualize the spatial distribution pattern of Aβ peptides (Kakuda, 
Miyasaka, Iwasaki, Nirasawa, & Wada-kakuda, 2017). By using the SA matrix and 
one of three methods for matrix deposition (airbrush, ultrasonic sprayer or automatic 
sprayer) and the Rapiflex instrument (Bruker Daltonics). This enabled identification 
of a distinct distribution pattern of senile plaques in AD brain tissue that was 
associated with Aβ peptide variants (Kakuda et al., 2017). The study used formic acid 
(vapor) pretreatment that was reported to improve detection of Aβ peptides. The study 
was the first to report detection of pyro-glu modified Aβ species in human AD brain 
tissue using MALDI-MS imaging. In addition to the pyro-glu modified Aβ, they also 
detected a variety of different Aβ species, such as Aβx-40 and Aβx-42 (x = 2, 4, 5, 6, 
7, 8, 9 and 10) (Ikegawa et al., 2019; Kakuda et al., 2017) (Table 1-1).  
Together, several studies have used MALDI-MS imaging to investigate senile plaques 
in tg mice and AD brain tissue. The studies have been performed over many years and 
a notable difference can be observed across the studies (Table 1-1). Part of these have 
been general methodological improvements in the MALDI-MS imaging field such as 
optimization of the sample preparation and instrumentational equipment. The studies 
have focused on elucidating unknown features that are associated with senile plaques 
such as detection of co-localizing Aβ species or using high spatial resolution imaging 
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to detect differences in the lipid composition across senile plaques. LMD has been 
used as a tool to enrich plaque regions and to increase the validity of the detected 
peptides (both Aβ species and lipids). Additionally, approaches that could enable 
detection of modified species like the pyro-glu modified Aβ have been addressed.  
These improvements are crucial for ensuring detection of Aβ peptides that otherwise 
might be missed in MALDI-MS imaging analysis and potentially lead to false-
negative conclusions. One study reported that the tgAPPArcSwe mouse strain 
encompasses several truncated Aβ species associated with senile plaques (Carlred et 
al., 2016). Other studies reported that senile plaques include a limited number of Aβ 
species such as Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40 and Aβ1-42 and Aβ1-42 Ox using 
the same tg strain or tgAPP23 mice (Kaya et al., 2018; Michno et al., 2018; Stoeckli 
et al., 2002). Furthermore, studies investigating the senile plaque composition from 
AD patients have found a complex senile plaque composition that encompass a variety 
of modified and truncated Aβ species (Table 1-1; (Ikegawa et al., 2019; Kakuda et 
al., 2017)). Reviewing these studies indicated differences in the senile plaque 
composition which could be dependent on the choice of tg mouse strain or matrix. 
Additionally, a more complex plaque composition has been implied in AD compared 
to tg mice, but a direct comparison, using the same experimental setup, has not been 













Table 1-1: Beta-amyloid (Aβ) species detected with MALDI-MS imaging. Ox = 
oxidation (M+16). Arc = peptide corresponding to mutation in the tgArcSwe mouse 
model. 2,5-DHA = 2,5-dihydroxyacetophenone. sDHB = super 2,5- 
dihydroxybenzoic acid. 3- or 11pE = truncated and pyroglutamate modified Aβ. 
Study Species Matrix Aβ species 
(Stoeckli et al., 
2002) 
Mouse SA Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, 
Aβ1-42, Aβ1-42 Ox. 





Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, 
Aβ1-42. 
(Stoeckli et al., 
2006) 
Mouse SA Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, 
Aβ1-42. 






Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, 
Aβ1-42. 
(Kelley, Perry, 
Castellani, et al., 
2016) 
Human DHB Aβ1-16, Aβ1-24, Aβ5-40, Aβ14-
40, Aβ1-42. 
(Carlred et al., 2016) Mouse CHCA 
Aβ1-42arc Ox, Aβ1-42arc, Aβ1-
40arc [M+Na]+, Aβ1-40arc, 3pE-
42, Aβ1-39arc, Aβ5-43 Ox, Aβ3-
40arc [M+Na]+, Aβ1-38arc 
[M+Na]+, Aβ1-38arc, Aβ2-39arc, 
Aβ1-37arc. 
(Kakuda et al., 2017) 
Human SA 
Aβx-40 and Aβx-42 (x = 1, 2, 3pE, 




et al., 2017) 
Mouse 2,5-
DHA 
Aβ1-37, Aβ1-38, Aβ1-40. 
(Kaya et al., 2018) 
Mouse 2,5-
DHA 
Aβ1-37, Aβ1-38, Aβ1-40, Aβ1-42. 
(Michno et al., 2019) 
Mouse 2,5-
DHA 
Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, 
Aβ1-42. 
(Ikegawa et al., 
2019) 
Human SA 
Aβx-40 and Aβx-42 (x = 1, 2, 3pE, 
4, 5, 6, 7, 8, 9, 10, and 11pE), Aβ1-
43. 
 







APPPS1-21: mAβ11-42, Aβ8-40, 
Aβ1-38, mAβ1-40, Aβ1-40, mAβ1-
42, Aβ1-42, Aβ1-42 Ox, Aβ1-43, 
Aβ1-43 Ox. 
Human: Aβ1-29, 11pE42, Aβ11-
42, 11pE43, Aβ1-31, Aβ10-42, 
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Table 1-1 continued 
 
 
Aβ9-42, Aβ1-32, Aβ8-42, Aβ8-
42Ox, Aβ1-33, Aβ8-43, Aβ7-42, 
Aβ7-43, Aβ6-42, Aβ5-42, 3pE40, 
Aβ4-42, 3pE42, Aβ1-40, Aβ2-42, 
Aβ1-42, Aβ1-42 Ox, Aβ1-43, Aβ1-
43 Ox. 
 
1.5.2. MICROPROTEOMIC ANALYSIS OF SENILE PLAQUES  
Introduction to LC-MS/MS and microproteomics 
Advancements in proteomic studies in relation to liquid chromatography tandem-mass 
spectrometry (LC-MS/MS) have enabled high-throughput analysis platforms that are 
capable of elucidating complex biological systems (Pirmoradian et al., 2013). In brief, 
a diluted sample is eluted through an electrospray ionization (ESI) source that 
generates an electrospray process by subjecting a high voltage to produce polarized 
droplets (Wong, Meng, & Fenn, 1988; Yamashita & Fenn, 1984). The solvent 
flowrate ranges from low nanoliter to microliter per minute depending on factors such 
as used emitter, column diameter and chromatography setup. As the solvent droplets 
are released from the source emitter they reduce in size due to solvent evaporation. 
Repeatedly, the charged droplets will implode into smaller droplets because of 
coulombic repulsive forces and eventually become charged solvent-free ions that can 
be guided through the mass spectrometer (reviewed by (Ho et al., 2003; Wilm, 2011)). 
ESI is characterized as a soft ionization technique with generation of multiple charged 
ion species which is different from MALDI-MS that generally produce single charged 
molecular ions. For proteomic applications several mass analyzer configurations can 
be applied. Most state-of-the-art mass spectrometers are equipped with a mass 
analyzer that is TOF- or orbitrap-based (Meier et al., 2018; Scheltema et al., 2014). 
The orbitrap uses an electric field to trap ions in an orbital motion. In the latter, the 
frequency of rotation is related to the m/z ratio and thus used to determine the m/z 
value of the ions (reviewed by (Xuemei Han, Aslanian, & Yates, 2008)).   
Two proteomic approaches are generally used; top-down and bottom-up. In top-down 
proteomics, an intact protein is separated by LC, electrosprayed and analyzed by a 
37 
mass spectrometer (reviewed by (Aebersold & Mann, 2016)). In contrast, the bottom-
up workflow begins with digestion of a protein mixture using a sequence specific 
enzyme such as trypsin, followed by LC separation, electrospray ionization and 
analysis by the mass spectrometer (Figure 1-6). The bottom-up acquisition is 
typically achieved with one of three common strategies; data-dependent acquisition 
(DDA), targeted, and data-independent acquisition (DIA; (Aebersold & Mann, 
2016)). As the DDA method and the closely related parallel accumulation serial 
fragmentation (PASEF; (Meier et al., 2018)) method were used in this PhD thesis, the 
focus will be on these workflows in the following section.  
In brief, the DDA method on a mass spectrometer can be divided into two processes: 
first, a collection of ionized peptides within a full spectrum (also referred to as MS1 
level) is used for selection of precursor ions. Second, a collection of precursor ions is 
subjected to fragmentation, typically by collision-induced dissociation (CID) or 
higher-energy collisional dissociation (HCD) to create a fragmentation spectrum (also 
referred to as MS2 level) (reviewed by (Aebersold & Mann, 2016)). The data can be 
analyzed by protein identification algorithms that use peptide and protein databases 
to identify the fragmented peptides. Other software’s can be used to statistically 
evaluate the identified proteins. As thousands of MS1 and MS2 events can be acquired 
from a single specimen, the DDA method has the capability of detecting thousands of 
proteins in one single analysis. Therefore, the DDA approach enables system-wide 
identification of biological systems by detecting changes in relative protein levels and 
direct protein-protein interactions (Choudhary & Mann, 2010). Subsequent analysis 
software with the STRING database as an example can be applied to map protein 
interactions by using direct and indirect associations (Szklarczyk et al., 2015). 
Furthermore, advanced developments have enabled interpretation of PTM 
fragmentation spectra, enabling both protein and PTM identification within a single 
dataset (Xi Han, He, Xin, Shan, & Ma, 2011; Nasiri Kenari et al., 2019). These 
technologies allow for large-scale proteomic studies that can elucidate complex 
molecular networks that previously were not feasible.  
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To elucidate protein networks, it can be an advantageous approach to accumulate and 
enrich a sample specimen of interest, prior to the mass spectrometry analysis. This 
increases the chance of detecting the central components in a network while limiting 
the inclusion of “irrelevant” proteins that can make the data interpretation difficult. 
As an example, complex pathologies like carcinomas can be critically enhanced by 
including normal surrounding tissue (De Marchi et al., 2016). LMD can greatly reduce 
such complexity by isolating homogenous sets of biological material interest from 
tissue sections and can be used to accumulate specific histological environments such 
as senile plaques that subsequently can be prepared for MS analysis (Lutz & Peng, 
2018). The amount of microdissected material in each sample can be minimal (e.g. 
nanogram-microgram range), hence the name microproteomics. 
 
 
Figure 1-6: Representation of a bottom-up workflow using the data-dependent 
acquisition (DDA) method. A protein mixture is digested by addition of a protease 
and peptides are separated using liquid chromatography (LC) followed by ionization 
and mass spectrometry analysis. Here, precursor ions are selected (MS1) and 
fragmented (MS2). The generated data is analyzed to identify features such as protein 
IDs, relative quantification intensities and pathway associations. The figure was made 
by Joakim Bastrup.   
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Microproteomic analysis of senile plaques 
Several proteomic studies have compared brain (or regional) homogenates from post-
mortem AD patients to control and identified differences in signaling pathways 
(Johnson et al., 2018; Seyfried et al., 2017). However, it is reasoned that proteomic 
changes related to senile plaques are difficult to extract from such data because of its 
relative limited presence compared to the remaining surrounding tissue that includes 
a heterogenous cell population. Plaque-associated changes may therefore be lost when 
analyzing whole tissue homogenates, supporting the use of microdissection. In 2004, 
such an approach was used by Liao and colleagues who dissected and studied 
thioflavin-S stained senile plaque and non-plaque material from two AD patients (10 
µm tissue section thickness (Liao et al., 2004)). Using LC-MS/MS analysis, 256 
proteins were found to be shared between the plaque extracts from the two patients. 
Of these, 26 proteins were found to be enriched in senile plaques compared to non-
plaque control regions. On the technical side, samples were separated on an SDS-gel 
and in-gel trypsin digestion was used. Approximately 500 senile plaques were 
extracted per sample and analysis was performed on an LCQ-DECA XP-Plus ion 
mass spectrometer (Liao et al., 2004). Additionally, the Sequest algorithm software 
(Eng, McCormack, & Yates, 1994) was used for the proteome analysis (Table 1-2).  
In 2017, Drummond and colleagues used microdissection to extract antibody stained 
senile plaques from rapidly progressive (n = 22) and SAD patients (n = 22) (8 µm 
tissue section thickness) (Drummond et al., 2017). In total, 279 proteins were 
consistently identified from every patient using LC-MS/MS analysis. FFPE tissue was 
used with pretreatment (deparaffinization and formic acid) and between 733 and 751 
senile plaques, were extracted per sample. Mass spectrometry analysis was achieved 
on a Q Exactive mass spectrometer instrument and the label-free quantification (LFQ) 
analysis was performed with MaxQuant and subsequently Perseus for bioinformatic 
analysis (Drummond et al., 2017).  
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Table 1-2. Comparison of microproteomic studies analyzing the senile plaque 
proteome. SAD = sporadic Alzheimer’s disease. APPPS1-21 = transgenic mouse 

















(Liao et al., 
2004) 
AD (n = 2) 10 µm 500 NA 188 
(Drummond 
et al., 2017) 
SAD (n = 
22) 
8 µm 733 - 751 ~61 µm 279 
(Xiong, Ge, 
& Ma, 2019) 
AD (n = 3) 
& 
APPPS1-
21 (n = 6) 
35 µm 3000 
80 - 100 
µm 
AD = 3848 
& 
APPPS1-






21 (n = 6) 
25 µm 300 ~85 µm 183 
 
In 2019, Xiong and colleagues used microdissection to extract stained senile plaques 
(Amylo-Glo RTD plaque staining reagent, Biosensis) from three AD patients, three 
age-matched healthy controls, six tgAPPPS1 mice and three non-tg wildtype 
littermates (~12.5-month-old mice; 35 µm tissue section thickness) (Xiong et al., 
2019). The study identified close to 4000 proteins that were consistent across senile 
plaque samples from the three AD patients. By comparing senile plaque extracts to 
adjacent control regions in both tgAPPPS1-21 mice and AD, they identified distinct 
patterns of regulated pathways (Xiong et al., 2019). In tgAPPPS1-21 mice, proteins 
associated with TYROBP causal network, microglia pathogen phagocytosis pathway, 
complement and coagulation cascade were mostly regulated. Proteins associated with 
complement activation, inflammatory response and allograft rejection were mostly 
regulated in AD samples (Xiong et al., 2019). Based on these findings, the study 
concluded that the protein composition in senile plaques from tgAPPPS1-21 mice and 
AD patients was different. Notably, the diameter of each extracts was 80-100 µm with 
approximately 3000 dissections from each brain sample resulting in a large amount of 
starting material (≥ previous studies, including our work in publication II). Tandem 
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mass tag (TMT)-labeling was used, samples were analyzed on an Orbitrap Fusion 
Lumos Tribrid Mass spectrometer and quantification analysis was performed with the 
Proteome Discoverer software (Xiong et al., 2019). 
Together, these studies have observed that senile plaque extracts encompass 100-
1000s of proteins in both the tgAPPPS1-21 mouse and AD brains, despite the use of 
different mass spectrometry instruments and identification software (Table 1-2). 
Approximately 256 - 279 plaque-associated proteins have consistently been observed 
in studies when extracting between 500 and 751 extracts from AD patients, 
respectively (Drummond et al., 2017; Liao et al., 2004). A recent study identified 3848 
proteins when increasing both the tissue thickness to 35 µm and the number of 
extracted plaques to approximately 3000 (Table 1-2; (Xiong et al., 2019)).  
The microproteomic approach in the three studies listed here have been used to 
describe the current molecular processes occurring within and around senile plaques 
by associating the proteins to pathways and cellular compartments. Furthermore, the 
co-localization of several proteins has been validated by fluorescent 
immunohistochemistry and microscopy imaging (Drummond et al., 2017; Liao et al., 
2004). The imaging analysis has been based on objective lenses with a 20X-40X 
magnification and the validation has therefore been focused on co-localization rather 
than co-aggregation with Aβ because of the limited degree of high resolution by these 
objective lenses.  
PTM analysis of the dissected senile plaque material has not been investigated in these 
studies (Drummond et al., 2017; Liao et al., 2004; Xiong et al., 2019). Since 
aggregated Aβ peptides have been reported to encompass a variety of different PTMs, 
it is considered relevant to apply the algorithms that enables PTM identification of the 
proteomic data due to their possible pathological involvement (See sections, 
Amyloid-β peptides, aggregation and senile plaque deposition, and Introduction 
to LC-MS/MS and microproteomics).   
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CHAPTER 2. OBJECTIVES 
AD is currently one of the biggest healthcare challenges worldwide, but despite 
several clinical trials no disease modifying treatments are available for treating the 
devastating disease. Senile plaques are one of the major hallmarks of AD and thought 
to be critically involved in the initial stages of AD pathogenesis. Understanding the 
molecular complexity of senile plaques may enable identification of targets that can 
lead to novel treatment strategies. MALDI-MS imaging is an emerging technology 
that enables label-free detection, identification and distribution of molecules. Previous 
studies using MALDI-MS imaging, have reported a diverse senile plaque composition 
which highlights the importance of optimizing the method to increase sensitivity and 
detection of Aβ species. 
New improvements in microproteomics enable unbiased identification of biological 
systems and can be used to understand the local proteomic processes occurring within 
and around senile plaques. Recent advancements in PTM analysis enables PTM 
analysis within LFQ data and thus creates a possibility of adding another dimension 
to the protein analysis. It is thought that such additional information could be valuable 
for treatment strategies targeting Aβ and senile plaques.  
 
This PhD thesis aimed to use MALDI-MS imaging and a microproteomic approach 
to investigate the underlying molecular features of senile plaques in AD and 
tgAPPPS1-21 mice. These technologies have been used to study the peptidomic and 
proteomic alterations in AD and tgAPPPS1-21 brain tissue. Additionally, microscopy 
imaging analysis has been used to validate the plaque-association of two proteins that 
were identified by our microproteomic approach. Two chronic antibody treatment 
studies with gantenerumab and aducanumab targeting different Aβ epitopes have been 
performed in tgAPPPS1-21 mice to elucidate the modulation of clearance 
mechanisms and of the protein composition of senile plaques.       
 
 







Overall objectives:  
 
I. Determine the peptidomic profile of Aβ species in senile plaques from 
AD and tgAPPPS1-21 mouse brains (included in publication I).  
 
II. Determine the proteomic profile, including PTMs, of senile plaques 
compared to surrounding tissue in tgAPPPS1-21 mouse brains (included 
in publication II). Investigate the senile plaque-association of selected 
identified proteins by microscopy imaging (included as preliminary 
data). 
 
III. Determine the proteomic profile of senile plaques after an anti-Aβ 
antibody treatment targeting Aβ in the tgAPPPS1-21 mice (included in 
manuscript III). 
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CHAPTER 3. METHODOLOGICAL 
CONSIDERATIONS 
This chapter describes the methodological considerations that were utilized in the 
course of this PhD work. These explanations are referring to the experiments in the 
publications and manuscript. A description of the experimental methods and materials 
is provided in the attached publications and manuscript. 
3.1. CHOICE OF MOUSE MODEL 
The generation of several tg amyloid-models is based on FAD mutations like the 
mutations in the APP, PSEN1, or PSEN2 genes. For this PhD thesis the tgAPPPS1-21 
strain was used because of its robust Aβ accumulation and well-characterized 
phenotype that has been widely used in previous studies, including treatment studies 
(Bittner et al., 2012; Radde et al., 2006; Ulrich et al., 2014). The tgAPPPS1-21 strain 
is created on a C57BL/6J genetic background and designed with the Swedish mutation 
in the APP gene (K670/671NL) as well as a mutation in the PSEN1 gene (L166P). 
These mutations cause increased production and accumulation of Aβ peptides that can 
be detected in the neocortex after approximately six weeks of age (Radde et al., 2006). 
The brain levels of Aβ1-42 is higher compared to Aβ1-40 which is similar to the Aβ1-
42/Aβ1-40 ratio observed in CSF from AD patients (Radde et al., 2006). Early signs 
of neurodegeneration measured on dendritic spine loss can be observed after 
approximately 10 weeks. For the studies described in this thesis, female mice were 
used in the age range from 8- to 12 months. This age range was chosen for two main 
reasons: 1) the mice have excessive senile plaque deposition in the entire brain 
enabling the possibility of analyzing specific brain regions such as the cerebral cortex 
or hippocampus, and 2) ensuring a possibility of comparison to longitudinal antibody-
treatment studies. It was decided to focus on female mice to avoid a potential gender-
associated difference and because female tgAPPPS1-21 mice have been reported to 
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express a higher senile plaques load compared to male tgAPPPS1-21 mice (Ulrich et 
al., 2014).  
3.2.      SENILE PLAQUE STAINING METHODS 
Senile plaques are usually distinguishable by their morphology in which they are 
referred to as “primitive”, “classic” or “compact/burned out” (Probst et al., 1987). 
Based on these morphological differences, several staining methods were considered 
prior to the experiments. For example, staining with fluorescent dyes can detect 
protein aggregates by interacting with beta sheet structures such as congo red and 
thioflavin-S or -T. Additionally, Aβ targeting antibodies like 6E10 (BioLegend) or 
D54D2 (Ambient), can bind to specific Aβ epitopes and therefore both methods have 
advantages and disadvantages. Stainings using the fluorescent dyes for aggregated 
proteins are relatively fast (~30 minutes) and easy to apply but increase the risk of 
false-positive inclusion of other proteins due to unspecific binding of β-sheet 
conformational structures. On the other hand, immunostainings with anti-Aβ 
antibodies are specific but more labor intensive with several longer incubation times 
and buffer changes (days). Therefore, thioflavin -T and -S stainings were preferred 
prior to mass spectrometry analysis (when using the LMD approach). Notably, diffuse 
plaques are weakly stained by thioflavin and therefore most detected plaques are 
neuritic when using this dye (Bussière et al., 2004). To limit the risk of including 
false-positive regions, careful examination of plaque-morphology was also applied by 
using a 20X objective lens. Furthermore, a head-to-head comparison of the thioflavin-
T and 6E10 staining was performed on adjacent tgAPPPS1-21 mouse brain tissue 
sections in publication II, validating that senile plaques were exclusively visualized 
by thioflavin-T.  
3.3. MALDI-MS IMAGING EXPERIMENTS 
Several MALDI-MS imaging studies have visualized senile plaques and reported a 
diverse plaque composition (See section, MALDI-MS imaging of senile plaques). 
Notably, different matrices have been used while the matrix additives have been 
limited to TFA. PA has been reported to reduce signal suppression effects in MALDI-
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MS studies and it was therefore hypothesized that adding this matrix additive to the 
sDHB matrix could increase the S/N ratio of Aβ peptides. It was decided to use a low 
spatial resolution for the comparison to the other matrices (CHCA/TFA, SA/TFA, 
sDHB/TFA) to limit matrix deterioration and thus a potential bias.   
The sublimation deposition approach has been used to study senile plaques (Kelley, 
Perry, Castellani, et al., 2016). Sublimation results in a uniform and homogenous 
crystal layer with limited risk of analyte diffusion. The reproducibility between 
sublimation and automatic sprayers such as the ImagePrep, have been found to be 
similar (Gemperline, Rawson, & Li, 2014). However, the ImagePrep sprayer enables 
the possibility of controlling the matrix thickness and wetness by an optical sensor 
that monitors light scattering from the matrix during the deposition. Both factors affect 
the efficiency of analyte extraction and incorporation into the matrix microcrystal 
lattice. As the aim in publication I was to compare matrices across several brain 
sections, this feature was found important to ensure a reliable comparison.  
The Ultraflextreme instrument has been widely used in previous studies investigating 
senile plaques in tg mouse models and AD brain tissue. We similarly used this 
instrument in our analysis and used the software, SCiLS Lab (Bruker Daltonics), to 
process and analyze the MALDI-MS imaging data. SCiLS Lab includes tools like 
mass spectral pre-processing, spatial visualization, principal component analysis 
(PCA), clustering analysis, statistical analysis, identification of discriminative m/z 
values between samples and detailed peak reports that were found useful in the 
analysis. For example, the top hat baseline pre-processing feature was used in this 
work because of the ability to reduce and smooth the baseline. Additionally, the total 
ion count (or current) (TIC) normalization method was used for spectral comparison.  
3.4. MICROPROTEOMIC STRATEGY 
Microdissection and LC-MS/MS analysis of senile plaques has been achieved in both 
fresh frozen and FFPE tissue (Drummond et al., 2017; Xiong et al., 2019). A study 
observed that LC-MS/MS analysis of FFPE preserved tissue increased the number of 
artificial modifications compared to fresh frozen tissue (Bennike et al., 2016). Based 
on this observation and our aim to detect modifications on proteins co-localizing with 
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senile plaques, it was decided to use fresh frozen tissue. Our study differed from the 
previously mentioned plaque-analyzing studies in that: 1) We used a detergent 
enhanced solubilization strategy with low volume acid-labile surfactant. 2) We used 
25-um-thick tissue sections for microdissection. 3) We used a match-between-run 
strategy matching ID’s to a pooled higher intensity sample. The previous plaque-
analyzing studies have used tissue sections of different thickness: 8-, 10- and 35-µm 
(Table 1-2; (Drummond et al., 2017; Liao et al., 2004; Xiong et al., 2019)). Senile 
plaques vary in size (10 – 100 µm in diameter) and so care was taken to ensure the 
quality of the microdissection. For example, when increasing the tissue thickness and 
microdissection area, the risk of including surrounding non-plaque tissue also 
increases. Based on this reasoning, it was decided to use 25-µm-thick tissue section 
and keep the dissection area close the senile plaque periphery.    
Senile plaque reduction was observed in the hippocampal region of the aducanumab 
treated mice which limited the area that could be used for microdissection in the 
samples. The increased sensitivity of the trapped ion mobility spectrometry (Tims)-
TOF Pro instrument compared to Q-Exactive HF-X was therefore considered to be 
advantageous because of the limited sample amount that was acquired in the 
microdissection from the aducanumab study (~90 and 300 plaque dissections per 
sample in manuscript III and publication II, respectively). Additionally, a direct 
infusion setup was used in manuscript III to increase the sensitivity even further.  
3.5. ANTIBODY TREATMENT STUDY DESIGN 
Two chronic anti-Aβ antibody treatment studies using gantenerumab and aducanumab 
were performed during the PhD work. The antibody treatment strategies were based 
on previous publications as well as in-house experience. Bohrmann and colleagues 
used tgPS2APP mice that were 5- to 6-months old and administered a weekly dose of 
gantenerumab for 5-months (20 mg/kg body weight; human IgG1 backbone; 
intravenous (i.v.) via the tail vein) (Bohrmann & Baumann, 2012). Similarly, 
Jacobsen and colleagues performed a chronic study with weekly dosing of 
gantenerumab (20 mg/kg body weight) in tgAPPLondon mice (human APP isoform 695 
with London mutation V717I). The mice were 13.5-month-old at beginning of dosing 
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and treated for 4-months (Jacobsen et al., 2014). Based on these studies, it was decided 
to use 4-month old tgAPPPS1-21 mice and to apply the same chronic dosing strategy 
of gantenerumab in this PhD work (weekly administration, 20 mg/kg, i.v.; 4-month 
administration, mouse IgG2a backbone). Notably, the senile plaque deposition can be 
observed after approximately 9- and 10-months of age in the tgPS2APP and 
tgAPPLondon model, respectively. Therefore, 4-months of age was chosen because the 
tgAPPPS1-21 mice start to show a robust plaque deposition at this age. In tgAPPPS1-
21 mice, senile plaque deposition can already be observed after approximately 1.5-
months of age in the cortex while the deposition in hippocampus begins after 3- to 4-
months (Radde et al., 2006).     
In 2016, Sevigny and colleagues reported that a weekly dose of chimeric (ch) 
aducanumab for 6-months significantly reduced the senile plaque load in 9.5-month 
old tg2576 mice (Sevigny et al., 2016). The antibody was administered by 
intraperitoneal (i.p.) delivery and was most efficacious at the 10 and 30 mg/kg per 
doses (Sevigny et al., 2016). A chronic study in-house using a weekly dose (10 mg/kg; 
i.p.) in 6-month old tgAPPPS1-21 mice observed significant reduction of senile 
plaques in both cortex and hippocampus after a 4-month treatment (personal 
communication with Dr. Lone Helboe, H. Lundbeck A/S). Based on the successful in-
house data, it was decided to replicate that study design (weekly dose of aducanumab; 
10 mg/kg; human IgG1 backbone; i.p.; tgAPPPS1-21 mice; 6-month of age at the 
beginning of the study; 4-month duration). 
Two control groups were used in both antibody treatment studies in this PhD work; 
one treated with PBS and one treated with a non-targeting and isotype control (IgG1). 
Mice were group housed, provided with enrichment, and had access to water and food 
ad-libitum. The administration methods were practiced on another cohort of mice 
prior to the two antibody studies to limit any effects of animal handling such as stress 
and other confounding factors that could affect the study outcome. 
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3.6. AN IMAGING APPROACH TO VALIDATE IDENTIFIED 
SENILE PLAQUE PROTEINS  
We decided to use a novel technique called protein-retention expansion microscopy 
(ProExM) to validate the presence of two proteins that were identified in the 
microproteomic approach (publication II). ProExM involves incorporation of a 
swellable gel that can be utilized to physically enlarge a specimen (Chen, Tillberg, & 
Boyden, 2015). The technique results in a 4-5 times isotropic expansion that enables 
imaging at nanoscale resolution with conventional microscopical equipment. Recent 
methodological advancements have included anchoring of conventional antibodies 
into the swellable gel and thereby allowed the use of regular fluorescent antibody 
staining (Tillberg et al., 2016) (Figure 3-1).  
 
 
Figure 3-1: Methodological workflow of protein-retention expansion microscopy 
(ProExM). Mouse brain is fixed in paraformaldehyde (PFA) and sectioned into 100 
µm tissue thickness. B) Antigen retrieval with formic acid and heat to increase 
penetration of antibodies used for immunostaining (triangles). C) Amines on 
biomolecules are modified with acryloyl-X (circle) to create an acrylamide group that 
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subsequently is incorporated into the gel (Tillberg et al., 2016). D) Triggering of 
gelation and subsequent digestion using Proteinase K. E) Expansion of tissue section 
when incubating in water. F) imaging with confocal setup using a water-immersion 
objective lens (20X/1.0). The figure was made by Joakim Bastrup. 
Senile plaques can vary greatly in size (10-100 µm in diameter) and inclusion of thick 
tissue sections are therefore advantageous when imaging senile plaques in their unity. 
On the other hand, immunohistochemistry of thick tissue sections can introduce 
several staining issues by poor antibody penetration. It was therefore decided to use 
100 µm thick tissue sections and two antigen retrieval steps prior to immunostaining; 
1) incubation in formic acid (80%) and 2) treatment with a detergent-rich buffer and 
heat. Additionally, we used four days of incubation with primary antibodies. We 
found that these steps combined, resulted in an efficient staining when using primary 
antibodies like the 6E10 (anti beta-amyloid), GA524 (astrocyte marker) and Ab5076 
(microglia marker; data not shown). Although several different microscopic 
approaches such as light-sheet or super-resolution techniques could have been used to 
image the stained and expanded tissue-gels, we found that an upright confocal 
microscope was most beneficial (for example due to the capability of fast orientation 
within the expanded tissue). The system was equipped with a water-immersion 
20X/1.0 objective lens with high working distance (WD; 2 mm). The relative low 
resolution but high numerical aperture (NA) and WD was found to be advantageous 
because the expansion factor provided morphological details that could be detected 
by the high NA while the WD enabled acquisition throughout the expanded samples. 















[Page left blank intentionally] 
53 
CHAPTER 4. RESULTS AND 
DISCUSSION 
4.1. MAIN FINDINGS  
This chapter focuses on the main findings and novelty from the publications and 
manuscript written during the PhD project. Additionally, preliminary data from the 
ProExM experiments are included. The chapter ends with a general discussion of the 
main findings and how these findings from tgAPPPS1-21 mice can be related with 
AD pathology.  
4.1.1. PUBLICATION I 
In publication I we reported a dual strategy that used two approaches to reduce signal 
suppression effects and increase detection of Aβ peptides in MALDI-MS imaging. 
We found that a parallel approach with LMD and PA together with the sDHB matrix 
greatly improved the S/N of Aβ peptides from senile plaques from both AD and 
tgAPPPS1-21 mouse brain tissue sections. The positive effect on ionization by PA as 
matrix additive to the sDHB matrix was particularly relevant when studying AD brain 
tissue. We observed a highly complex Aβ plaque composition with high levels of 
truncated and modified forms such as pyro-glu modified Aβ which was not observed 
in the tgAPPPS1-21 mice. The data indicated that tgAPPPS1-21 mice express a less 
complex senile plaque Aβ peptide profile compared to AD. 
4.1.2. PUBLICATION II 
In publication II we reported a microproteomic strategy to identify and analyze 
proteins co-localizing with Aβ in senile plaques isolated from the tgAPPPS1-21 mice. 
Three regions: senile plaques, adjacent control regions from tgAPPPS1-21 mice and 
similar regions from wildtype littermates, were microdissected and analyzed. This 
approach enabled characterization of molecular processes occurring within and 
around senile plaques, including identification of unique PTM profiles. Our approach 
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identified 183 proteins that were consistently observed across senile plaque extracts. 
By using LFQ, we identified 27 proteins co-localizing with senile plaques that were 
significantly regulated when comparing senile plaques to adjacent control regions. 
These proteins indicated different biological processes in which the upregulated 
proteins were associated with endocytosis and metabolism, and the downregulated 
proteins were associated with neuronal cytoskeleton. Our unbiased PTM analysis 
identified 193 and 117 modifications that were exclusive to proteins co-localizing 
with either senile plaques or adjacent control extracts, respectively. The identification 
of such exclusive PTMs is a novel finding and adds an additional layer of complexity 
to senile plaques from tgAPPPS1-21 mice that we are the first to address.  
4.1.3. VALIDATION OF TWO IDENTIFIED PLAQUE-ASSOCIATED 
PROTEINS 
Our microproteomic data supports the notion that a complex interplay between plaque 
and brain cells was occurring. We reasoned that detailed imaging techniques could 
elucidate this interaction better. For example, super-resolution techniques have 
successfully visualized nanoscale details of amyloid fibrils in both tgAPP mice and 
AD brain using antibody staining (Blazquez-Llorca, Merchán-Pérez, Rodríguez, 
Gascón, & DeFelipe, 2013; Mlodzianoski et al., 2019; Querol-Vilaseca et al., 2019). 
However, super-resolution techniques are challenged by penetration depth in tissue 
(very high magnification objective lenses depend on the use of short WD). This 
limitation becomes specifically relevant when imaging matured plaque structures that 
can reach up to 100 µm in diameter. Based on these challenges, we turned to ExM 
(Chen et al., 2015). This method has been reported to enable physical expansion of 
tissue sections by approximately 4-5 times the original size. The method is based on 
linking water-absorbing polymers to biomolecules within a tissue section, which 
enables expansion once exposed to water. Since most of the tissue will contain water, 
the tissue specimen becomes transparent which is favorable for imaging thick tissue 
sections (Chen et al., 2015). A recent optimization of the method, enabled 
incorporation of antibodies to the polymers, enabling combination with fluorescent 
immunohistochemistry (Tillberg et al., 2016) (Figure 3-1 in previous chapter).  
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The remaining section focuses on preliminary data that were acquired with this 
technique. We are the first to report that the ProExM protocol can be applied on senile 
plaques from tgAPPPS1-21 mice.  
 
Figure 4-1: Validation of protein-retention expansion microscopy (ProExM) method 
on senile plaques in transgenic APPPS1-21 mouse brain sections. Anti-beta-amyloid 
(Aβ) immunostaining before A) and after B) ProExM protocol. C) Representation of 
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distance measurements and calculated expansion factor in A) and B). White lines 
indicate amyloid structures that were measured. Images were acquired with the same 
water-immersion objective lens (20X/1.0) and settings. Scale bar 50 µm. D) Tilescan 
stack (3x3) of expanded tissue (beta-amyloid (Aβ; green; 6E10, BioLegend) and 
astrocytes (red; GA524, DAKO)). Scale bar = 100 µm. E) Single-plane images of 
region of interest (white box in D). Scalebar = 50 µm. F-H) shows orthogonal view of 
Aβ fibril in E)  (within white box). Scalebar = 5 µm. I) Plot profile illustrating the 
diameter (x,y dimension) of the selected Aβ fibril in F). J) Double immunostaining of 
Aβ (red) and enolase-1 (ENO1, Santa-Cruz) protein (green). Cellular morphology is 
indicated by dotted lines. Scale bar 10 µm. K-L) Double immunostaining of Aβ K) 
and phosphoglycerate kinase 1 (PGK1, Santa-Cruz; L). M) Overlay of K) and L). 
Scale bar = 20 µm.  
We found that including antigen retrieval prior to immunostaining, increased the 
penetration depth of antibodies (data not shown). Furthermore, we compared a section 
stained with an anti-Aβ antibody (6E10, BioLegend) before and after expansion. This 
enabled us to compare and measure the expansion factor, which in this case was found 
to be approximately three times the original size (Figure 4-1A-C). After establishing 
that ProExM could expand senile plaques, we investigated the capability of resolving 
fine amyloid structures. By using a tile-scan function, we were able to resolve both 
mature plaques and association to surrounding astrocytes (GA524 antibody, DAKO) 
as well as fine structures such as Aβ fibrils (Figure 4-1D,E). The diameter of these 
fibrils was approximately 1 mm (x,y dimension), meaning that the ProExM method 
could resolve structures between 200-300 nm when extracting the expansion factor 
(Figure 4-1E-I).  
Using this method, we investigated whether we could detect two proteins co-
localizing in senile plaques that were identified in publication II. Enolase-1 (ENO1) 
and phosphoglycerate kinase 1 (PGK1) are both associated with glycolysis (Kim & 
Dang, 2005). We observed that ENO1 (sc-271384, Santa-Cruz) immunoreactivity was 
localized next to senile plaques (Figure 4-1J), suggesting it may be expressed in the 
surrounding glia. On the other hand, PGK1 (sc-48342, Santa-Cruz) was highly co-
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localized with senile plaques (Figure 4-1K-M) suggesting a true-plaque association. 
These findings underlined the importance of validating the precise localization of 
proteins by imaging techniques following their identification by MS. A description of 
the protocol is included in (Appendix A).     
4.1.4. MANUSCRIPT III 
In manuscript III we reported an MS-based investigation of proteomic patterns 
associated with senile plaque extracts and surrounding tissue in tgAPPPS1-21 mice 
after treatment with an anti-Aβ targeting antibody. Initially, we determined the 
treatment effect of two antibodies, gantenerumab and aducanumab, by measuring the 
senile plaque load with thioflavin-S. We identified a significant reduction of senile 
plaques in the hippocampal brain region of tgAPPPS1-21 mice treated with 
aducanumab compared to controls and focused on this area in the subsequent 
microproteomic analysis. Additionally, we utilized MALDI-MS imaging to 
investigate the senile plaque composition in the frontal cortex of the tgAPPPS1-21 
mice that supported a limited effect of the antibody in the cortical regions. Our 
microproteomic strategy of the hippocampus was based on three tissue extracts: senile 
plaque, senile plaque penumbra, and an additional ring to the penumbra (referred to 
as SP, SPP-L1, and SPP-L2 in manuscript III). We identified a proteomic similarity 
between the respective subregions, as several proteins were shared. For example, 216, 
315 and 395 proteins were detected in SP, SPP-L1, and SPP-L2 extracts from the three 
treatment groups, respectively. However, our statistical analysis identified that these 
proteins (especially in SPP-L1 and SPP-L2 subregions) were regulated when 
comparing the respective LFQ levels across the groups. Here, a difference was 
observed in the SPP-L1 and SPP-L2 subregions between the treatment groups where 
we identified 18 and 15 differentiating proteins, respectively. Using pathway analysis, 
we associated these proteins to different pathways and found that proteins related to 
energy metabolism were increased in tgAPPPS1-21 mice dosed with aducanumab. 
Furthermore, an increased regulation of the astrocytic marker, glial fibrillary acidic 
protein (GFAP), was observed in SPP-L1 regions from aducanumab treated mice 
compared to the unspecific IgG group. Our data suggested increased recruitment of 
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glia cells to senile plaques in the aducanumab treated mice. Interestingly, we also 
observed differences in proteomic patterns of nucleoside diphosphate kinase A 
(NME1) and syntenin-1 (SDCBP) across the subregions within each treatment group. 
These are GTPase regulating proteins and have been reported to be involved in 
phagocytosis, endocytosis and lysosomal degradation. The regulation of these 
proteins was mainly observed in aducanumab treated mice and could explain part of 
the plaque degradation caused by aducanumab’s action.        
4.2. DISCUSSION OF MAIN FINDINGS AND ASSOCIATION WITH 
AD 
The work presented focused on elucidating the underlying molecular complexity of 
senile plaques in AD and tgAPPPS1-21 mice. We investigated this at a peptidomic 
level in publication I where we observed a variety of Aβ peptides co-localizing with 
Aβ1-42 in both AD and tgAPPPS1-21 mouse brains using an optimized MADLI-MS 
imaging protocol. Our parallel approach with PA and LMD increased the detection of 
Aβ proteoforms, including pyro-glu modified species in brain tissue from AD patients. 
The detection of pyro-glu modified Aβ in AD brain tissue was recently reported with 
SA as matrix and vapor pretreatment with formic acid (Kakuda et al., 2017). Notably, 
we detected this modification when using PA as additive to the sDHB matrix without 
pretreatment, indicating an advantage of using PA. Matrix additive variants were 
previously reported to improve ion formation and S/N ratio of phosphopeptides and 
non-phosphopeptides in a direct comparison to PA (Kuyama et al., 2008). Thus, we 
consider that using e.g. methanediphophonic acid in combination with the sDHB 
matrix might improve the S/N ratio of Aβ proteoforms even further.  
Senile plaques in tgAPPPS1-21 mice encompassed mainly full-length peptides such 
as Aβ1-40, Aβ1-42 and Aβ1-43 while senile plaques in AD brain tissue encompassed 
a variety of truncated and modified Aβ species. Thus, a central difference in the senile 
plaque composition was observed in the brains of tgAPPPS1-21 mice and AD 
patients. We reason that this observation could be due to several factors such as: 1) 
Aβ peptides are reported to be processed by extracellular proteases, possibly leading 
to truncated forms (Cataldo, Thayer, Bird, Wheelock, & Nixon, 1990; Smith, Kalaria, 
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& Perry, 1993). However, the aggressive overproduction of Aβ in combination with 
rapid fibril formation (the kinetics of Aβ) might hamper such processing by rapid 
aggregation which could result in a rapid senile plaque deposition in the tgAPPPS1-
21 mice and explain the relative high levels of full-length Aβ peptides. 2) Multiple 
enzymes are involved in cleavage of Aβ in AD. It might be that part of these are 
missing or reduced in the tgAPPPS1-21 mice which similarly could lead to deposition 
of full-length Aβ peptides. Despite these differences the tgAPPPS-21 model did 
express an abundant level of Aβ1-42 within senile plaques which was also observed 
as the most abundant species in AD brains and supports its applicability.       
Recent in-house immunohistochemistry data showed minimal reactivity of antibodies 
targeting pyro-glu modified Aβ in 9-month old tgAPPPS1-21 mice while a higher 
reactivity was observed in 12-month old mice (data not shown, personal 
communication Dr. Lone Helboe, H. Lundbeck A/S). This finding was in line with 
our observation of lacking pyro-glu modified Aβ in 9-month old tgAPPPS1-21 mice. 
We have not analyzed 12-month old tgAPPPS1-21 mice but consider that the 
modification might be detectable in older mice with MALDI-MS imaging. We reason 
that the appearance of this modification could be considered in future studies using 
the tgAPPPS-21 mouse strain given the likely involvement of pyro-glu modified Aβ 
species in AD. Furthermore, the Aβ species profile could be investigated further as 
these appear to be a central difference between senile plaques from tgAPPPS1-21 and 
AD brains. The tgAPPPS1-21 mouse strain is designed to overexpress two FAD 
mutations that model an aggressive amyloidopathy. MALDI-MS imaging analysis of 
brain tissue from FAD patients carrying one of these mutations would be valuable to 
elucidate whether a comparable Aβ peptide composition with truncated and/or full-
length Aβ peptides is observed. If so, Aβ compositions in senile plaques from FAD 
would differ from SAD brains and therefore it could be considered to use tgAPPPS1-
21 mice prior to clinical trials focusing on treating FAD rather than SAD patients.  
In publication II we applied a microproteomic strategy to investigate proteins and 
PTMs in senile plaques and surrounding tissue extracts from tgAPPPS1-21 mice. We 
identified 22 up- and 5 downregulated proteins by comparing proteome data from 
senile plaques and surrounding tissue. Using literature-based pathway analysis, we 
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observed that the upregulated proteins were associated with metabolic pathways (e.g. 
glycolysis), endocytosis and vesicle-transport, implying that several regulatory 
processes were occurring within the senile plaques. This approach was considered 
valuable due to the possibility of determining protein changes associated with plaque-
brain interaction pathways which were necessary for answering objective III in the 
thesis. One limitation with the MS method was the lack of ability to localize the 
identified proteins and clarify whether they were truly associated with the senile 
plaques. For example, aggregated Aβ peptides are engaged by glia cells and several 
proteins in a microdissected plaque extract could therefore be associated with the 
cellular environment. This was supported by the identification of several proteins that 
were associated with e.g. glycolysis. Thus, it was reasoned that combination with 
other techniques like ProExM imaging was relevant for clarifying this association. 
Therefore, we optimized the ProExM protocol to enable detailed imaging of senile 
plaques in brain tissue from tgAPPPS1-21 mice. We clarified a distinct senile plaque-
association of ENO1 and PGK1, both of which were identified in publication II and 
manuscript III. Our data showed that the ENO1 did not co-localize with the senile 
plaque structures but was associated with morphologies next to senile plaques. This 
observation may be explained by engaging glial cells such as microglia or astrocytes. 
We consider that a triple staining visualizing both Aβ, ENO1 and either microglia or 
astrocytes could be beneficial to confirm this finding. On the other hand, we are the 
first to visualize that PGK1 co-localized with amyloid aggregates. It should be 
emphasized that we used the same anti-mouse secondary antibodies for detecting 
ENO1 and PGK1 and that the gain and laser power were kept at a minimum to limit 
the possibility of autofluorescence or cross excitation and thus a potential false-
positive detection of senile plaques. The fact that we did not detect amyloid structures 
with the ENO1 immunohistochemistry supports this reasoning. PGK1 is a key enzyme 
in glycolysis and gluconeogenesis but altered levels of this protein has previously 
been linked to AD pathology (Ho Kim et al., 2015). Notably, PGK1 has been reported 
as a cargo protein in exosomes and ectosomes (reviewed by (Meldolesi, 2018)). Glial 
cells release exosomes and ectosomes as part of their Aβ processing and we therefore 
consider that this could explain the pathway from the intracellular to the extracellular 
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position. Vimentin and annexin, two other cargo proteins that are also associated with 
exosomes and ectosomes (Meldolesi, 2018) have similarly been detected in previous 
LC-MS/MS studies of microdissected plaque material which supports this idea 
(Drummond et al., 2017; Liao et al., 2004). PGK1 was recently reported as a 
therapeutic target in Parkinson’s disease that similarly is characterized by aggregation 
and deposition of α-synuclein into Lewy bodies (Cai et al., 2019). Cai and colleagues 
observed that treatment with terazosin increased the activity of PGK1 and enhanced 
glycolysis which slowed the disease progression of Parkinson’s disease. Thus, we 
consider that treatment with terazosin may also be a therapeutic approach in AD.   
Our PTM analysis identified several exclusive modifications in senile plaque extracts 
such as oxidation, deamidation, pyro-glu, citrullination and ISD (z + 2)-series. The 
ISD (z + 2)-series identification was primarily identified on proteins associated with 
senile plaques (12 sites vs 2 sites on proteins associated with adjacent control). These 
proteins were 14-3-3 protein isoforms, APP, Beta-actin-like protein 2, Excitatory 
amino acid transporter 2 and Tubulin alpha chain isoforms. The modification refers 
to one type of fragment ions observed in a tandem MS spectrum and therefore not a 
biological modification. This was not anticipated but we speculate that it could be due 
to side-chain fragmentation generating z-ions during the dissociation, although further 
studies are needed to elucidate this finding. Oxidation, deamidation, pyro-glu and 
citrullination have been associated with AD and our detection of these modifications 
was therefore in-line with previous findings (Adav et al., 2016; Hensley et al., 1995; 
Ishigami et al., 2005; Sullivan et al., 2011). Several modifications have been reported 
on Aβ, but the fact that proteins co-localizing with senile plaques also are subjected 
to modifications adds another layer of complexity that could have pathological 
impact. For example, an exclusive pyro-glu modification was identified on CLU in 
senile plaque extracts in our study. Despite the identification of CLU as a susceptible 
gene in GWAS, CLU has also been reported to co-aggregate with Aβ (Lambert et al., 
2013; Oda et al., 1995). It remains to be elucidated whether such modification alters 
the biological function of CLU and thus also Aβ toxicity. 
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We identified a total of 183 proteins that were consistently observed in senile plaque 
extracts from the tgAPPPS1-21 mouse strain. One of the aims in publication II was to 
determine whether tissue-associated differences between senile plaques and adjacent 
control regions in the tgAPPPS1-21 also were observed in AD. At the time of our 
experiment three comprehensive studies that investigated the senile plaque proteome 
in AD patients had been published, so we compared our findings with the published 
data. Since approximately 70% of the detected proteins in our study were present in 
the consistent proteins observed by Drummond and colleagues, we considered that a 
general proteomic profile of senile plaques was conserved across tgAPPPS1-21 mice 
and AD (Drummond et al., 2017). The number of consistent proteins was lower in our 
study compared to recently published studies analyzing senile plaque extracts from 
AD brains (183 vs 188, 279 and 3848, respectively; (Drummond et al., 2017; Liao et 
al., 2004; Xiong et al., 2019)). This could be explained by regional and 
methodological differences in sample preparation, tissue thickness, mass spectrometer 
instrument and analyzing software as mentioned previously (See section, 
Microproteomic analysis of senile plaques).  
Based on the findings from publication I and II, a central difference in the Aβ peptide 
profile was observed between tgAPPPS1-21 mice and AD patients while a similarity 
was observed at a proteomic level. Together, the data suggested that the response 
mechanism in the tgAPPPS1-21 mouse brain could replicate the coping mechanisms 
to Aβ accumulation observed in AD. This seemingly contradicting finding is critical 
when performing anti-Aβ treatment experiments with the tgAPPPS1-21 mouse model. 
On one hand, the model resembles a comparable cellular coping mechanism to Aβ 
accumulation. On the other hand, the model accumulates Aβ aggregates that not 
resemble a true-plaque peptide-composition seen in AD. Thus, it is considered that 
the tgAPPPS1-21 mouse is a mechanistic model of AD. It can be debated, whether 
the outcome of an anti-Aβ antibody treatment in this model can be translated to the 
effect on senile plaques in AD. For example, antibodies targeting truncated Aβ species 
could result in a false-negative conclusion when using the tgAPPPS1-21 model (<10-
month old). Aducanumab was reported to interact with AA sequence 3-6 of Aβ. The 
level of full-length Aβ (Aβ1-42) was abundant in both tgAPPPS1-21 mice and AD 
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and the action of aducanumab was therefore considered to be effective in both. 
Although not the scope of this thesis, we consider that the action of aducanumab could 
be limited by possibly excluding pyro-glu modified Aβ and truncated Aβ in AD.   
Our histological examination of senile plaque load in tgAPPPS1-21 mice treated with 
aducanumab demonstrated significant clearance in the hippocampus compared to 
control. The clearance mechanism by aducanumab has been reported to occur via glia 
cell recruitment (Sevigny et al., 2016). To capture this event, we microdissected senile 
plaques and surrounding penumbra. Our proteomic analysis of SP extracts suggested 
a degree of similarity between the treatment groups by having several shared proteins 
with limited differences in intensity levels after LFQ. In contrast, notable differences 
were observed across SPP-L1 and SPP-L2 subregions in the three groups, as we 
identified 18 and 15 significantly differentiating proteins, respectively. Furthermore, 
several proteins associated with energy metabolism were increased in the aducanumab 
treated mice. This finding was in line with our hypothesis, as we anticipated the 
engagement of aducanumab would cause recruitment of glia cells that subsequently 
would initiate phagocytosis and increase their energy metabolism. We observed 
increased levels of the astrocytic marker, GFAP, in the SPP-L1 region of aducanumab 
treated mice compared to IgG which supported this. Furthermore, we identified 
increased levels of proteins associated with phagocytosis like plastin-2 (LCP1) and 
phosphatidylinositol 4-phosphate 5-kinase type-1 gamma (PIP5K1C) in the SPP-L1 
region when comparing aducanumab to IgG treated mice (1.79-fold, p = 0.097; 2.03-
fold, p = 0.067; LCP1 and PIP5K1C, respectively; student t-test, 0.1 FDR) 
(Kwiatkowska & Sobota, 1999; Morley, 2012). Our findings from publication II 
indicated increased levels of proteins associated with endocytosis and energy 
metabolism when comparing senile plaques to surrounding tissue. This finding was 
also supported by the data in manuscript III which indicated that these pathways and 
especially proteins associated with energy metabolism were detected in senile plaques 
and closely surrounding regions.  
Our anticipation of glia recruitment by aducanumab was based on microproteomic 
data and we consider that validating this finding with other techniques such as 
immunohistochemistry would be beneficial. It was reported that the level of the 
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lysosomal marker, CD68, correlated with Aβ1-42 load in patients from the active 
vaccine (AN-1792) program (See section, Treatment strategies targeting amyloid-
β) (Zotova et al., 2011). Zotova and colleagues observed co-localization of CD68 and 
microglia and suggested that a subgroup of microglia were recruited to senile plaques 
to initiate phagocytosis (Zotova et al., 2011). Additionally, the authors reported 
differences in microglia activity depending on the Aβ pathology (high plaque load 
resulted in increased levels of CD68+ microglia while low plaque load resulted in 
decreased levels of CD68+ microglia). We consider that such cellular subpopulation 
would be interesting to target in the aducanumab treated tgAPPPPS1-21 mice from 
our study, as they could represent the proteomic profile that we detected. We 
identified two GTPase regulating proteins which intensity levels were altered 
specifically by the aducanumab treatment. Phagocytosis and associated degradation 
of material is regulated by several GTPases (Mao & Finnemann, 2015; Yeo, Wall, 
Luo, & Stow, 2016). GTPase regulating proteins are therefore considered highly 
relevant in respect to clearance of senile plaques. NME1 was observed to be reduced 
in all subregions from aducanumab compared to controls and did not differentiate as 
seen in the control groups. In contrast, SDCBP was regulated by aducanumab and 
observed to be abundant in SP extracts. Our data could therefore suggest that part of 
the clearance mechanism of aducanumab could be caused by recruitment of a specific 
subtype of glia cells that host these protein patterns. Different clearance mechanisms 
have been hypothesized by anti-Aβ targeting antibodies. Our data support a central 
clearance mechanism by aducanumab that is mediated by glia recruitment to the 
penumbral region of senile plaques to elicit its effect.  
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CHAPTER 5. CONCLUSIONS 
The presented dissertation has focused on determining different layers of molecular 
complexity that are associated with senile plaques in both AD and tgAPPPS1-21 
model mice.  
We reported a parallel approach by combining microdissection and MALDI-MS 
imaging to overcome issues related to signal suppression hampering the detection of 
Aβ proteoforms. Additionally, we demonstrated that the use of PA as matrix additive 
to the sDHB matrix improved the detection of Aβ peptides in MALDI-MS imaging. 
Using this approach, we identified a central difference in the senile plaque (Aβ-
associated) composition between AD and 9-month old tgAPPPS1-21 mice. We report 
that senile plaques from AD patients are composed of more truncated and modified 
Aβ proteoforms compared to tgAPPPS1-21 mice.  
We reported a microproteomic strategy that enabled isolation and determination of 
the proteomic profile of senile plaques and surrounding tissue in tgAPPPS1-21 mice. 
We identified several differentiating proteins that demonstrated regulatory processes 
associated with endocytosis and metabolism within senile plaque extracts. 
Furthermore, several exclusive PTMs such as oxidation, deamidation and pyro-glu 
were identified on the proteins co-localizing with senile plaque extracts in the 
tgAPPPS1-21 mouse model. Using ProExM, we observed co-aggregation of PGK1 
which was identified by our microproteomic approach.  
We found that chronic treatment with the anti-Aβ targeting antibody, aducanumab, 
significantly reduced the senile plaque load in hippocampus compared to the control 
groups. Using the MS-based strategies, we demonstrated that the proteomic 
complexity of the closely located penumbral region of senile plaques was affected by 
the treatment. Our data supported that the clearance mechanism by aducanumab 
occurred via glia cell recruitment and possibly through increased energy metabolism 
and modulation of GTPase regulating proteins that are involved in phagocytosis.  
We believe that our findings have clarified part of the molecular complexity 
associated with senile plaques in the tgAPPPS1-21 mouse model. Our data has 
contributed to a general understanding of molecular processes occurring in senile 
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plaques, closely surrounding tissue and how it is affected by an anti-Aβ targeting 
antibody. The identification of regulated proteins and PTMs could lead to novel drug 













CHAPTER 6. PERSPECTIVES 
The results presented in this dissertation suggest that several proteins including their 
modified forms are co-localizing and/or co-aggregating with aggregated Aβ. It is 
essential to elucidate the biological function of these proteins and PTMs as they could 
have a beneficial or detrimental impact on disease pathogenesis and future studies 
should therefore investigate these mechanisms. Three-dimensional neuronal co-
cultures consisting of human cell types expressing FAD mutations are suggested as a 
simple and relative fast method to answer these questions (Choi et al., 2014). Such a 
method would allow establishment of a platform that could be used to both visualize 
the many proteins e.g. with microscopy and screen the effect of compounds that 
specifically target these proteins. The knowledge, and ideally new targets uncovered 
from such experiments could be used in combination with current antibody therapies 
to boost the treatment effect or overcome the weaknesses of current antibody 
therapies. It is noteworthy that a high load of senile plaques was still present in both 
gantenerumab and aducanumab mice after chronic treatment. This may suggest that 
these antibodies are not capable of removing all senile plaques or that the kinetics of 
plaque clearance in AD cannot be adequately modeled in tg mice. It is considered that 
finding alternative approaches to reach these subtypes of senile plaques could 
optimize clearing efficiency. 
Both MALDI-MS imaging and microproteomics are relatively young scientific fields 
that have challenges which future studies should address. For example, sensitivity 
issues in MALDI-MS imaging are currently a major limitation that hampers the 
outcome. We addressed this issue in (publication I), but it is considered that further 
optimization of the method would be beneficial. A recent advancement of MALDI-
MS imaging, termed MALDI-2, argues that the low sensitivity is a consequence of 
poor ionization and reports the use of a secondary post-ionization process increases 
the sensitivity several orders of magnitude (Soltwisch et al., 2015). Similarly, 
microproteomic suffers from limited sample material and approaches that can ensure 
the maximum yield of each sample are highly valued. For example, DIA-based 
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methods such as DIA-PASEF could maximize the sample coverage and identification 
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Appendix A. Expansion microscopy 
Tissue dissection, antigen retrieval and immunostaining 
Animals were anesthetized with avertin (1ml/100 g) and transcardial perfused with 
KPBS containing heparin (two minutes; 12 ml/min flow) followed by 4% 
paraformaldehyde (PFA) (10 minutes; 12 ml/min flow). Brains were incubated 
overnight (O/N) in 4% PFA solution at 4°C, washed and stored in KPBS/0.01% 
sodium azide until further use. Brains were cryoprotected by immersing in 30% 
sucrose (w/v) in KPBS for two days on shake at 4°C prior to freezing with dry ice and 
sectioning 100 µm coronal sections on a cryostat (Leica CM3050 S). Sections were 
stored in 1.5 ml tubes containing KPBS/0.01% sodium azide at 4°C.   
Antigen retrieval was performed by incubating tissue sections in 80% formic 
acid/ddH2O for 15 minutes at room temperature (RT) followed by heat treatment 
(95°C) in an alkaline buffer for 10 minutes (100 mM Tris base, 5% (w/v) triton X-
100, 1% sodium dodecyl sulfate (SDS) in water. Tissue sections were washed twice 
in 1XPBS (five minutes each, RT, shake) between and after the antigen retrieval. The 
tissue sections were permeabilized in blocking buffer (1XPBS, 1% bovine albumin 
serum (BSA), 0.3% triton X-100, 5% normal swine serum (NS)) for five hours at RT 
on shake. Mouse antibodies (1:100, mouse 6E10, BioLegend; 1:100, mouse MN1060, 
Invitrogen; 1:50, mouse sc-271384, Santa-Cruz; 1:100, mouse sc-48342, Santa-Cruz; 
1:100, rabbit D54D2, Ambient; 1:400, rabbit GA524, DAKO; 1:100, goat Ab5076, 
Abcam) were tested for four days, followed by incubation with (1:200; αMouse, 
αGoat or αRabbit; all IgG (H+L) secondary antibodies conjugated with alexa flour 
488, 555 or 647, respectively (Thermo Fisher) for six hours at RT on shake. Sections 
were incubated in washing buffer (1XPBS, 0.25% BSA, 0.1% triton X-100) 4 x 15 
minutes in between and after antibody staining at RT on shake.          
Gelation, digestion, expansion and mounting 
The stained sections were incubated in acryloyl-X SE/anhydrous (AcX, Invitrogen, 
prepared in dimethyl sulfoxide (DMSO), Sigma) O/N at RT on shake, washed twice 
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in 1XPBS for 15 minutes and incubated in gelation solution (monomer solution, 
0.01% w/v 4-Hydroxy-TEMPO (4-HT; Sigma), 0.2% v/v tetramethylethylenediamine 
(TEMED; Sigma), 0.2% w/v ammonium persulfate (APS; Sigma)) for two hours in 
humidified 37°C incubation chamber. Monomer solution was prepared by mixing 
8.6% w/v sodium acrylate (Sigma), 2.5% w/v acrylamide (Sigma), 0.15% v/v N,N’-
methylenebisacrylamide (Sigma), 11.7% w/v sodium chloride, 1XPBS. Tissue-gels 
were incubated O/N at RT in digestion buffer containing; 0.5% triton X-100, 0.2% 
ethylenediaminetetraacetic acid (EDTA) (0.5M, pH 8), 5% Tris HCl (1M, pH 8), 4.67 
g NaCl, proteinase K (final conc. 8 U/ml; New England Biolabs). Tissue-gels were 
expanded by incubating in ddH2O four times for 15 minutes. Imaging was conducted 
on an LSM 880 upright confocal setup (Zeiss).  
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